



*Public Health Act 2005*

# Public Health Regulation 2005

Current as at 30 June 2017





Queensland

# Public Health Regulation 2005

## Contents

---

|                   |  | Page |
|-------------------|--|------|
| <b>Part 1</b>     | <b>Preliminary</b>   |      |
| 1                 | Short title .....  | 5    |
| 2                 | Commencement .....   | 5    |
| 2AA               | Dictionary .....   | 5    |
| <b>Part 1A</b>    | <b>Public health risks</b>   |      |
| <b>Division 1</b> | <b>Asbestos</b>  |      |
| 2A                | Purpose and application of div 1 .....   | 5    |
| 2B                | Definitions for div 1 .....  | 6    |
| 2C                | Administration and enforcement of div 1 .....  | 7    |
| 2D                | Removal of friable asbestos .....  | 8    |
| 2E                | Removal of bonded ACM .....  | 8    |
| 2F                | Cleaning or cutting ACM .....  | 8    |
| 2G                | Requirement to seal bonded ACM if broken .....                                       | 9    |
| 2H                | Requirement to take reasonable measures to minimise release of asbestos fibres ..... | 10   |
| 2I                | Packaging and disposal of associated asbestos waste .....                            | 11   |
| 2J                | Prohibition on selling or giving away ACM .....                                      | 11   |
| <b>Division 2</b> | <b>Mosquitos</b>   |      |
| 2K                | Purpose of div 2 .....   | 12   |
| 2L                | Definitions for div 2 .....  | 12   |
| 2M                | Administration and enforcement of div 2 .....  | 12   |
| 2N                | Requirement to ensure place is not a breeding ground for mosquitos .....             | 13   |
| 2O                | Construction, installation and maintenance of a relevant tank ..                     | 13   |
| 2P                | Requirements for a relevant tank .....   | 14   |
| 2Q                | Offence to damage screen or flap valve .....   | 14   |
| <b>Division 3</b> | <b>Rats and mice</b>   |      |
| 2R                | Purpose of div 3 .....   | 14   |

Contents

---

|                   |   |    |
|-------------------|---|----|
| 2S                | Definition for div 3 .....  | 15 |
| 2T                | Administration and enforcement of div 3 .....   | 15 |
| 2U                | Requirement for owner of relevant structure .....   | 15 |
| 2V                | Offence to damage screen etc. on relevant structure .....   | 16 |
| 2W                | Requirement to ensure rats or mice do not live or breed on land around dwelling .....                               | 16 |
| 2X                | Requirements about keeping rats or mice as pets etc. ....   | 17 |
| <b>Division 4</b> | <b>Other public health risks</b>  |    |
| 2XA               | Invasive procedures—Act, ss 11 and 18 .....   | 17 |
| <b>Part 1B</b>    | <b>Water risk management plans</b>  |    |
| 2Y                | Prescribed tests—Act, s 61A .....   | 18 |
| 2Z                | Prescribed requirement—Act, s 61D .....   | 18 |
| 2ZA               | Prescribed reporting period—Act, s 61I .....  | 18 |
| <b>Part 2</b>     | <b>Notifiable conditions</b>  |    |
| 3                 | Notifiable condition—Act, s 64(1), definition notifiable condition .  | 19 |
| 4                 | Clinical diagnosis notifiable condition—Act, s 62, definition clinical diagnosis notifiable condition .....         | 19 |
| 5                 | Pathological diagnosis notifiable condition—Act, s 62, definition pathological diagnosis notifiable condition ..... | 19 |
| 6                 | Pathology request notifiable condition—Act, s 62, definition pathology request notifiable condition .....           | 20 |
| 7                 | Provisional diagnosis notifiable condition—Act, s 62, definition provisional diagnosis notifiable condition .....   | 20 |
| 8                 | Controlled notifiable condition—Act, s 63(1), definition controlled notifiable condition .....                      | 20 |
| 9                 | Requirements for notice—Act, s 70(2)(a) .....   | 20 |
| 10                | Requirements for notice—Act, s 71(2)(a) .....   | 21 |
| 11                | Requirements for notice—Act, s 72(2)(a) .....   | 21 |
| 12                | Requirements for notice—Act, s 73(2)(a) .....   | 21 |
| 12AA              | Prescribed agreements—Act, s 84(1) .....  | 21 |
| <b>Part 2A</b>    | <b>Infection control</b>  |    |
| 12AB              | Prescribed health care facilities—Act, s 153(3) .....   | 22 |
| 12AC              | Prescribed health care facilities—Act, s 154(3) .....   | 22 |
| <b>Part 2B</b>    | <b>Child health—contagious conditions</b>   |    |
| 12B               | Contagious condition—Act, s 158, definition contagious condition  | 23 |
| 12C               | Requirements for vaccination—Act, s 158, definition vaccinated  | 23 |
| 12D               | Vaccine preventable condition—Act, s 158, definition vaccine preventable condition .....                            | 24 |

|                   |  |    |
|-------------------|--|----|
| 12E               | Prescribed period for a contagious condition—Act, s 160 . . . . .                                | 24 |
| <b>Part 2C</b>    | <b>Performance of cosmetic procedures on children</b>  |    |
| 12F               | Procedures that are not cosmetic procedures for Act, ch 5A—Act s 213A(2) . . . . .               | 24 |
| <b>Part 2D</b>    | <b>Disclosure of information for school health programs</b>                                      |    |
| 12G               | Prescribed information for school health programs—Act, s 213AD                                   | 26 |
| <b>Part 3</b>     | <b>Perinatal statistics</b>  |    |
| 13                | Notifications about perinatal statistics—Act, s 217 . . . . .                                    | 26 |
| 14                | Prescribed agreements—Act, s 226(1)(a)(i)(B) . . . . .   | 26 |
| <b>Part 4</b>     | <b>Maternal death statistics</b>   |    |
| 14A               | Notifications about maternal death statistics—Act, s 228F . . . . .                              | 26 |
| 14B               | Prescribed agreements—Act, s 228O(1)(a)(i)(B) . . . . .  | 27 |
| <b>Part 5</b>     | <b>Cancer notifications</b>  |    |
| 15                | Types of skin cancer and non-invasive carcinoma—Act, s 229, definition cancer . . . . .          | 27 |
| 15A               | Prescribed person—Act, s 232 . . . . .   | 27 |
| 16                | Notifications about cancer—Act, s 234(1)(b) and (3) . . . . .                                    | 27 |
| 17                | Prescribed agreements—Act, s 244(1)(a)(i)(B) . . . . .   | 28 |
| <b>Part 6</b>     | <b>Pap Smear Register</b>  |    |
| 18                | Clinical information—Act, s 251, definition clinical information . .                             | 28 |
| <b>Part 6A</b>    | <b>Water quality</b>   |    |
| <b>Division 1</b> | <b>Preliminary</b>   |    |
| 18AA              | Purpose of pt 6A . . . . .   | 29 |
| 18AB              | Definitions for pt 6A and schs 3A–3E . . . . .   | 30 |
| <b>Division 2</b> | <b>Standards for water quality—Act, s 461(2)</b>   |    |
| 18AC              | Drinking water . . . . .   | 31 |
| 18AD              | Recycled water supplied to augment a supply of drinking water .                                  | 32 |
| 18AE              | Class A+ recycled water . . . . .  | 33 |
| 18AF              | Class A, B, C or D recycled water . . . . .  | 33 |
| 18AG              | Recycled water for irrigation of minimally processed food crops                                  | 34 |
| 18AH              | Recycled water supplied for a dual reticulation scheme . . . . .                                 | 34 |
| <b>Part 7</b>     | <b>Miscellaneous</b>   |    |
| 18A               | Paint—Act, s 60 . . . . .  | 35 |
| 19                | Emergency officers (general)—Act, s 333(1)(e) . . . . .  | 35 |
| 20                | Human research ethics committee—Act, sch 2, definition human research ethics committee . . . . . | 35 |
| 20A               | Prescribed training for indemnity conditions—Act, s 454G . . . . .                               | 36 |

Contents

---

|                    |   |    |
|--------------------|---|----|
| <b>Part 8</b>      | <b>Transitional provisions</b>  |    |
| 21                 | Transitional asbestos removal licence or certificate . . . . .  | 36 |
| <b>Schedule 1</b>  | <b>Notifiable conditions</b> . . . . .  | 38 |
| <b>Schedule 2</b>  | <b>Immediate notifications</b> . . . . .  | 45 |
| <b>Schedule 2A</b> | <b>Contagious conditions</b> . . . . .  | 47 |
| 1                  | Definitions for sch 2A . . . . .  | 56 |
| <b>Schedule 2B</b> | <b>Vaccine preventable conditions</b> . . . . .   | 58 |
| <b>Schedule 3</b>  | <b>Agreements</b> . . . . .   | 59 |
| <b>Schedule 3A</b> | <b>Standards for quality of drinking water</b> . . . . .  | 61 |
| <b>Schedule 3B</b> | <b>Standards for quality of recycled water supplied to augment a supply of drinking water</b> . . . . . | 63 |
| <b>Schedule 3C</b> | <b>Standards for quality of class A+ recycled water</b> . . . . .                                       | 81 |
| <b>Schedule 3D</b> | <b>Standards for quality of classes A, B, C and D recycled water</b>                                    | 83 |
| <b>Schedule 3E</b> | <b>Standards for quality of recycled water for irrigating minimally processed food crops</b> . . . . .  | 85 |
| <b>Schedule 4</b>  | <b>Dictionary</b> . . . . .   | 88 |

---

# Public Health Regulation 2005

## Part 1 Preliminary

### 1 Short title

This regulation may be cited as the *Public Health Regulation 2005*.

### 2 Commencement

- (1) Parts 2 to 6 and 8, and schedules 1 to 3 commence on 1 December 2005.
- (2) Part 7 commences on 16 January 2006.

### 2AA Dictionary

The dictionary in schedule 4 defines particular words used in this regulation.

## Part 1A Public health risks

### Division 1 Asbestos

#### 2A Purpose and application of div 1

- (1) This division prescribes, under section 61(1)(c) of the Act, measures to prevent and control the public health risk mentioned in section 11(1)(b)(viii) of the Act in relation to the dispersal or release of asbestos fibres.
- (2) This division applies in relation to non-workplace areas.

## 2B Definitions for div 1

In this division—

**ACM** means any material, object, product or debris containing asbestos.

**asbestos** means the asbestiform varieties of mineral silicates belonging to the serpentine or amphibole groups of rock-forming minerals, including the following—

- (a) actinolite asbestos;
- (b) grunerite (or amosite) (brown) asbestos;
- (c) anthophyllite asbestos;
- (d) chrysotile (white);
- (e) crocidolite (blue);
- (f) tremolite asbestos;
- (g) a mixture containing 1 or more of the minerals mentioned in paragraphs (a) to (f).

*Note—*

Paragraphs (a), (b), (c) and (f) mention mineral silicates that use the same mineral term for both the asbestiform and nonasbestiform varieties. The word ‘asbestos’ has been included when listing these minerals to emphasise that only the asbestiform habit of these minerals is regulated as asbestos.

**associated asbestos waste** means—

- (a) ACM, other than a sample of ACM removed for scientific testing, that is removed in a non-workplace area, including ACM dust; or
- (b) disposable items contaminated with ACM.

*Examples for paragraph (b)—*

personal protective equipment, plastic sheeting and rags used for cleaning

**bonded ACM** means ACM, other than friable ACM, that contains a bonding compound reinforced with asbestos fibres.



*Examples—*

asbestos cement pipes, flat or corrugated asbestos cement sheets consisting of sand and cement reinforced with asbestos fibres

***friable ACM*** means ACM that, when dry, can be crumbled, pulverised or reduced to powder by hand pressure.

***non-workplace area*** means a place, or part of a place, that is not a workplace under the *Work Health and Safety Act 2011*.

*Note—*

See the *Work Health and Safety Act 2011*, section 8.

***prescribed work*** means—

- (a) doing any of the following in relation to ACM—
  - (i) breaking;
  - (ii) cleaning;
  - (iii) cutting;
  - (iv) maintaining;
  - (v) removing;
  - (vi) repairing;
  - (vii) storing;
  - (viii) using; or
- (b) separating associated asbestos waste from other waste.

***remove***, in relation to ACM, includes move the ACM from the position where it was installed immediately before 18 June 2007.

*Example of removing ACM—*

moving a sheet of ACM to access an area for maintenance

## **2C Administration and enforcement of div 1**

This division is to be administered and enforced by local governments only.

## **2D Removal of friable asbestos**

A person must not remove friable ACM unless the person holds a class A asbestos removal licence under the *Work Health and Safety Regulation 2011* authorising the removal.

Maximum penalty—100 penalty units.

## **2E Removal of bonded ACM**

- (1) A person must not remove a quantity of bonded ACM of more than 10m<sup>2</sup> unless the person holds a certificate under this section that is in effect and obtained under arrangements approved or established by the chief executive.

Maximum penalty—100 penalty units

- (2) To remove any doubt, it is declared that if more than 1 person is removing the bonded ACM mentioned in subsection (1), subsection (1) applies to each of the persons.
- (3) For subsection (1), the chief executive may approve or establish arrangements under which a person may obtain a certificate after completing training satisfactory to the chief executive in competencies decided by the chief executive.

*Examples—*

- 1 The chief executive approves a particular statement of attainment of an RTO as a certificate under this section.
  - 2 The chief executive establishes an interactive training course on the internet that issues certificates under this section to persons who successfully complete the course.
- (4) A certificate is in effect for a period fixed under arrangements mentioned in subsection (3).

## **2F Cleaning or cutting ACM**

- (1) A person must not use—
  - (a) a power tool, or a device attached to a power tool, to cut or clean ACM; or

*Examples—*

- using an electric sander to remove paint from asbestos cement sheeting
  - using an angle grinder to cut asbestos cement pipes
- (b) a high pressure water process to clean ACM; or

*Example—*

using a water blaster to clean an asbestos cement roof

- (c) compressed air to clean ACM or a surface where ACM is present.

*Examples—*

- using compressed air to clean an area after working with asbestos cement sheeting
- using compressed air to clean the brake drums of a car

Maximum penalty—100 penalty units.

- (2) In this section—

***power tool*** means an electric, battery, hydraulic, fuel or pneumatic powered tool, other than a battery powered drill that operates at less than 650r.p.m.

## **2G Requirement to seal bonded ACM if broken**

- (1) This section applies if—

- (a) a person is removing bonded ACM or carrying out specified work in relation to bonded ACM in a non-workplace area; and
- (b) the bonded ACM is broken.

- (2) The person must ensure a broken surface of the bonded ACM that is not being removed from the non-workplace area is sealed.

*Example of sealing a broken surface of bonded ACM—*

applying paint or PVA glue to the surface

Maximum penalty—100 penalty units.

- (3) In this section—

*specified work* means manufacturing, construction, repair, alteration, cleaning or demolition work.

## **2H Requirement to take reasonable measures to minimise release of asbestos fibres**

- (1) A person who carries out prescribed work must take reasonable measures to minimise—
- (a) the risk of asbestos fibres being released; and
  - (b) the associated hazard to the health of the person or any other person.

Maximum penalty—100 penalty units.

- (2) For subsection (1), reasonable measures may include 1 or more of the following—
- (a) spraying water or a coat of PVA glue on ACM or other associated asbestos waste;
  - (b) using vacuum cleaning equipment that complies with AS 3544 to collect asbestos fibres;
  - (c) cleaning all equipment that is contaminated with ACM;
  - (d) using a wet cloth to wipe away dust that may have originated from ACM;
  - (e) ensuring, as far as practicable, that ACM is not broken or abraded;
  - (f) wearing personal protective equipment to minimise the person's exposure to airborne asbestos fibres;
  - (g) collecting and handling associated asbestos waste separately from other waste.
- (3) Subsection (2) does not limit what might be reasonable measures.
- (4) In this section—

**AS 3544** means AS 3544 'Industrial vacuum cleaners for particulates hazardous to health' (1988).

---

## 2I Packaging and disposal of associated asbestos waste

- (1) A person who carries out prescribed work must ensure all associated asbestos waste is packaged and disposed of as soon as practicable in the way mentioned in subsection (2).

Maximum penalty—100 penalty units.

- (2) The associated asbestos waste must be—
- (a) either—
- (i) double wrapped in plastic sheeting that is at least 0.2mm thick and sealed with adhesive tape; or
  - (ii) double bagged in plastic bags that are at least 0.2mm thick, and no more than 1,200mm long and 900mm wide, and sealed with adhesive tape; and
- (b) labelled with a warning that is clearly visible and states that—
- (i) the packaging contains asbestos; and
  - (ii) damage to the packaging and dust inhalation should be avoided; and

*Example of warning—*

‘CAUTION - ASBESTOS  
DO NOT DAMAGE OR OPEN BAG  
DO NOT INHALE DUST  
CANCER AND LUNG DISEASE HAZARD’

- (c) disposed of at a site approved by a local government for the disposal of asbestos waste.

## 2J Prohibition on selling or giving away ACM

- (1) A person must not sell or give away ACM stored at a non-workplace area.

Maximum penalty—100 penalty units.

- (2) In this section—

*sell* includes barter, exchange or supply.

## **Division 2                      Mosquitos**

### **2K        Purpose of div 2**

This division prescribes, under section 61(1)(b) and (c) of the Act, measures to—

- (a) control mosquitos; and
- (b) prevent and control the public health risks mentioned in section 11(1)(a) and (b)(i) of the Act in relation to mosquitos.

*Note—*

Mosquitos are defined as *designated pests* in schedule 2 of the Act.

### **2L        Definitions for div 2**

In this division—

***mosquito*** includes a mosquito egg, larva, pupa and adult mosquito.

***relevant person***, for a place, means—

- (a) an occupier of the place; or
- (b) if there is no occupier of the place—an owner of the place.

***relevant tank*** means a tank or other receptacle that is used or intended to be used for holding or storing water or another liquid.

### **2M        Administration and enforcement of div 2**

This division is to be administered and enforced by local governments only.

---

**2N Requirement to ensure place is not a breeding ground for mosquitos**

- (1) A relevant person for a place must ensure that an accumulation of water or another liquid at the place is not a breeding ground for mosquitos.

Maximum penalty—40 penalty units.

- (2) For subsection (1), it is irrelevant whether the accumulation of water is artificial, natural, permanent or temporary.
- (3) In a proceeding for an offence against subsection (1), it is a defence for the defendant to prove that the defendant took all reasonable steps to ensure subsection (1) was complied with.
- (4) In this section—

***breeding ground***, for mosquitos, means a place where mosquito eggs, larvae or pupae are present.

*Examples of places where liquid may accumulate and become a breeding ground for mosquitos—*

bromeliads, containers, ditches, drains, gutters, car bodies, ponds, swimming and tidal pools, sump traps, tyres, tubs, water features

**20 Construction, installation and maintenance of a relevant tank**

- (1) A person must not construct a relevant tank unless the tank complies with section 2P.

Maximum penalty—40 penalty units.

- (2) A person must not install a relevant tank, whether above or below ground, unless the tank complies with section 2P.

Maximum penalty—40 penalty units.

- (3) A relevant person for a place at which a relevant tank is installed must ensure the tank is maintained so it continues to comply with section 2P.

Maximum penalty—40 penalty units.

## **2P Requirements for a relevant tank**

For section 2O, a relevant tank must have at every opening of the tank—

- (a) mosquito-proof screens that—
  - (i) are made of brass, copper, aluminium or stainless steel gauze; and
  - (ii) have a mesh size of not more than 1mm; and
  - (iii) are installed in a way that does not cause or accelerate corrosion; and
  - (iv) stop mosquitos passing through the openings; or
- (b) flap valves that, when closed, stop mosquitos passing through the openings.

## **2Q Offence to damage screen or flap valve**

- (1) A person must not destroy, damage or remove a mosquito-proof screen or flap valve fixed to a relevant tank.

Maximum penalty—40 penalty units.

- (2) However, subsection (1) does not apply to a person removing the mosquito-proof screen or flap valve to carry out maintenance, if the screen or flap valve is immediately replaced after the maintenance is completed.

## **Division 3 Rats and mice**

### **2R Purpose of div 3**

This division prescribes, under section 61(1)(b) and (c) of the Act, measures to—

- (a) control rats and mice; and
- (b) prevent and control the public health risks mentioned in section 11(1)(a) and (b)(i) of the Act in relation to rats and mice.



*Note—*

Rats and mice are defined as *designated pests* in schedule 2 of the Act.

## **2S Definition for div 3**

In this division—

***relevant structure*** means any of the following—

- (a) a building;
- (b) a drain;
- (c) a pipe connected to a building;
- (d) a retaining wall;
- (e) a wharf.

## **2T Administration and enforcement of div 3**

This division is to be administered and enforced by local governments only.

## **2U Requirement for owner of relevant structure**

- (1) An owner of a relevant structure must take reasonable steps to stop rats and mice entering the structure.

Maximum penalty—40 penalty units.

- (2) For subsection (1), reasonable steps may include the following—
  - (a) sealing or covering any holes or gaps in the exterior surface of the structure;

*Examples—*

- covering a gap in the floor or an external wall of a house with timber
- for a hole in the cladding of a brick house, filling it with mortar or covering it with a metal plate screwed to the wall
- filling a hole with chicken wire or covering it securely with a vermin-proof covering

[s 2V]

---

- (b) fitting a cover, grate or plug securely in a covered pipe or drain, including a disused pipe or drain;
  - (c) removing a disused pipe or drain.
- (3) This section does not apply in relation to rats or mice kept under section 2X.

## **2V Offence to damage screen etc. on relevant structure**

- (1) A person must not destroy, damage or remove a screen or other object that has been fixed to a relevant structure for the purpose of stopping rats and mice entering the structure.
- Maximum penalty—40 penalty units.
- (2) However, subsection (1) does not apply to a person removing the screen or other object to carry out maintenance, if the screen or object is immediately replaced after the maintenance is completed.

## **2W Requirement to ensure rats or mice do not live or breed on land around dwelling**

- (1) A relevant person for land around a dwelling must ensure—
- (a) rats or mice are not harboured on the land; and
  - (b) the land is not a breeding ground for rats or mice.
- Maximum penalty—40 penalty units.
- (2) In a proceeding for an offence against subsection (1), it is a defence for the defendant to prove that the defendant took all reasonable steps to ensure subsection (1) was complied with.
- (3) This section does not apply in relation to rats or mice kept under section 2X.
- (4) In this section—
- relevant person*, for a place, means—
- (a) an occupier of the place; or

- 
- (b) if there is no occupier of the place—an owner of the place.

**2X Requirements about keeping rats or mice as pets etc.**

- (1) This section applies to a person who keeps rats or mice—
- (a) as pets; or
  - (b) at a laboratory for medical, research, scientific or teaching purposes; or
  - (c) for the purpose of selling them, giving them away or using them as a food source for other animals.

- (2) The person must keep the rats or mice in an enclosure from which they can not escape.

Maximum penalty—40 penalty units.

- (3) This section does not limit an applicable local law about keeping rats or mice.
- (4) In this section—  
*sell* includes barter, exchange or supply.

**Division 4 Other public health risks**

**2XA Invasive procedures—Act, ss 11 and 18**

- (1) For section 11(1)(b)(xi) of the Act, an activity associated with, or part of, an invasive procedure that may expose a person to an infectious condition is prescribed.
- (2) The Act is to be administered and enforced for the public health risk mentioned in subsection (1) by the State only.
- (3) In this section—  
*invasive procedure* see section 147 of the Act.

## Part 1B Water risk management plans

### 2Y Prescribed tests—Act, s 61A

- (1) For the Act, section 61A, definition *prescribed test*, a test for Legionella is prescribed for chapter 2A of the Act if the test—
  - (a) quantifies the number of Legionella colony forming units in the sample tested; and
  - (b) is carried out by an accredited laboratory and is identified in the scope of the laboratory's accreditation.

- (2) In this section—

*accredited laboratory* means a laboratory accredited as complying with ISO/IEC 17025 by—

- (a) the National Association of Testing Authorities Australia ABN 59 004 379 748; or
- (b) another entity the chief executive is satisfied is appropriately qualified to accredit a laboratory as complying with ISO/IEC 17025.

*ISO/IEC 17025* means the standard published jointly by the International Organization for Standardization and the International Electrotechnical Commission as in force from time to time under that designation (regardless of the edition or year of publication of the standard).

### 2Z Prescribed requirement—Act, s 61D

For the Act, section 61D(g), a water risk management plan for a prescribed facility must identify the person, by position title, who is responsible for complying with sections 61H and 61I of the Act for the facility.

### 2ZA Prescribed reporting period—Act, s 61I

- (1) For the Act, section 61I(3), definition *reporting period* the following periods are prescribed—

- 
- (a) 1 February 2017 to 31 March 2017;
  - (b) after 31 March 2017—
    - (i) if the chief executive has given the prescribed facility notice stating reporting periods shorter than a quarter apply to the facility—the periods stated in the notice; or
    - (ii) otherwise—each quarter.
- (2) In this section—  
*quarter* means a 3 month period ending on 31 March, 30 June, 30 September or 31 December.

## Part 2 Notifiable conditions

### 3 Notifiable condition—Act, s 64(1), definition *notifiable condition*

For the definition *notifiable condition* in section 64(1) of the Act, the medical conditions mentioned in schedule 1, column 1 are notifiable conditions.

### 4 Clinical diagnosis notifiable condition—Act, s 62, definition *clinical diagnosis notifiable condition*

For paragraph (b) of the definition *clinical diagnosis notifiable condition* in section 62 of the Act, schedule 1, column 2 identifies which of the notifiable conditions mentioned in schedule 1, column 1 are clinical diagnosis notifiable conditions.

### 5 Pathological diagnosis notifiable condition—Act, s 62, definition *pathological diagnosis notifiable condition*

For paragraph (b) of the definition *pathological diagnosis notifiable condition* in section 62 of the Act, schedule 1, column 3 identifies which of the notifiable conditions

mentioned in schedule 1, column 1 are pathological diagnosis notifiable conditions.

**6 Pathology request notifiable condition—Act, s 62, definition *pathology request notifiable condition***

For the definition *pathology request notifiable condition* in section 62 of the Act, schedule 1, column 4 identifies which of the notifiable conditions mentioned in schedule 1, column 1 are pathology request notifiable conditions.

**7 Provisional diagnosis notifiable condition—Act, s 62, definition *provisional diagnosis notifiable condition***

For paragraph (b) of the definition *provisional diagnosis notifiable condition* in section 62 of the Act, schedule 1, column 5 identifies which of the notifiable conditions mentioned in schedule 1, column 1 are provisional diagnosis notifiable conditions.

**8 Controlled notifiable condition—Act, s 63(1), definition *controlled notifiable condition***

For the definition *controlled notifiable condition* in section 63(1) of the Act, schedule 1, column 6 identifies which of the notifiable conditions mentioned in schedule 1, column 1 are controlled notifiable conditions.

**9 Requirements for notice—Act, s 70(2)(a)**

For section 70(2)(a) of the Act, the notice must be given by fax, email or other electronic means—

- (a) for a clinical diagnosis notifiable condition or provisional diagnosis notifiable condition mentioned in schedule 2—immediately after the examination; or
- (b) for a clinical diagnosis notifiable condition or provisional diagnosis notifiable condition not mentioned in schedule 2—within 48 hours after the examination.

---

**10 Requirements for notice—Act, s 71(2)(a)**

For section 71(2)(a) of the Act, the notice must be given by fax, email or other electronic means—

- (a) for a clinical diagnosis notifiable condition or provisional diagnosis notifiable condition mentioned in schedule 2—immediately after the examination; or
- (b) for a clinical diagnosis notifiable condition or provisional diagnosis notifiable condition not mentioned in schedule 2—within 48 hours after the examination.

**11 Requirements for notice—Act, s 72(2)(a)**

For section 72(2)(a) of the Act, the notice must be given by fax, email or other electronic means—

- (a) for a pathological diagnosis notifiable condition mentioned in schedule 2—immediately after the pathological examination; or
- (b) for a pathological diagnosis notifiable condition not mentioned in schedule 2—within 48 hours after the pathological examination.

**12 Requirements for notice—Act, s 73(2)(a)**

For section 73(2)(a) of the Act, the notice must be given by fax, email or other electronic means—

- (a) for a pathology request notifiable condition mentioned in schedule 2—immediately after the receipt of the request; or
- (b) for a pathology request notifiable condition not mentioned in schedule 2—within 48 hours after the receipt of the request.

**12AA Prescribed agreements—Act, s 84(1)**

- (1) Each agreement mentioned in schedule 3, part 1, division 1 is prescribed for section 84(1)(a)(i)(B) of the Act.

- (2) Each agreement mentioned in schedule 3, part 1, division 2 is prescribed for section 84(1)(b)(i)(B) of the Act.

## **Part 2A                      Infection control**

### **12AB Prescribed health care facilities—Act, s 153(3)**

For section 153(3) of the Act, the following health care facilities are prescribed—

- (a) a health care facility owned by a local government, if the operator of the health care facility—
  - (i) performs an immunisation service at the health care facility; and
  - (ii) has developed and implemented at the health care facility an occupational exposure policy and a sharps disposal policy;
- (b) a health care facility owned by a doctor, if the doctor holds either—
  - (i) general practice accreditation from Australian General Practice Accreditation Limited ACN 077 562 406 or Quality in Practice Pty Ltd ACN 094 965 590; or
  - (ii) the accreditation named ‘GPA Accreditation plus’ from Quality Practice Accreditation Pty Ltd ACN 081 986 932.

### **12AC Prescribed health care facilities—Act, s 154(3)**

For section 154(3) of the Act, the following health care facilities are prescribed—

- (a) a health care facility owned and operated by a local government, if the local government—
  - (i) performs an immunisation service at the health care facility; and



- 
- (ii) has developed and implemented at the health care facility an occupational exposure policy and a sharps disposal policy;
  - (b) a health care facility owned and operated by a doctor, if the doctor holds either—
    - (i) general practice accreditation from Australian General Practice Accreditation Limited ACN 077 562 406 or Quality in Practice Pty Ltd ACN 094 965 590; or
    - (ii) the accreditation named ‘GPA Accreditation plus’ from Quality Practice Accreditation Pty Ltd ACN 081 986 932.

## **Part 2B**                      **Child health—contagious conditions**

### **12B**      **Contagious condition—Act, s 158, definition *contagious condition***

For the definition *contagious condition* in section 158 of the Act, the contagious medical conditions mentioned in schedule 2A, part 1 are contagious conditions.

### **12C**      **Requirements for vaccination—Act, s 158, definition *vaccinated***

- (1) This section prescribes, for the definition *vaccinated* in section 158 of the Act, the way for vaccinating a child for a vaccine preventable condition.
- (2) The way is for the child to receive all vaccinations for the condition recommended for the child’s age in the document called ‘National Immunisation Program Schedule’ (IMM66) published, from time to time, by the Department of Health and Ageing (Cwlth).

*Editor’s note—*

A copy of the document is available at [www.immunise.health.gov.au](http://www.immunise.health.gov.au).

**12D Vaccine preventable condition—Act, s 158, definition  
*vaccine preventable condition***

For the definition *vaccine preventable condition* in section 158 of the Act, the contagious conditions or other medical conditions mentioned in schedule 2B are vaccine preventable conditions.

**12E Prescribed period for a contagious condition—Act, s 160**

- (1) For section 160(2) and (3)(a) of the Act, the right column in schedule 2A, part 2 identifies the prescribed period for a contagious condition for a child suspected under chapter 5 of the Act of having the condition.
- (2) For section 160(3)(b) of the Act, the right column in schedule 2A, part 3 identifies the prescribed period for a contagious condition for a child who does not have the condition but who is suspected under chapter 5 of the Act of—
  - (a) not having been vaccinated for the condition; and
  - (b) being at risk of contracting the condition if the child continues to attend a school, education and care service or QEC approved service.

## **Part 2C Performance of cosmetic procedures on children**

**12F Procedures that are not cosmetic procedures for Act, ch  
5A—Act s 213A(2)**

- (1) For section 213A(2) of the Act, the following procedures are prescribed—
  - (a) a procedure involving the removal of a skin tag;
  - (b) a procedure involving the reshaping of the external structure of the ear, also known as otoplasty;

- (c) a procedure involving the reshaping of a hand or foot that is polydactyl or syndactyl;
  - (d) a procedure involving the circumcision of the penis;
  - (e) a procedure involving the correction of disfiguring scarring resulting from a medical condition, illness or trauma;
  - (f) a procedure involving the removal of a naevus that is disfiguring, melanotic or interferes with the function of a part of the human body;
  - (g) a procedure involving the removal of a tattoo;
  - (h) a procedure—
    - (i) that is part of a plan to treat a child; and
    - (ii) involving cranio-facial surgery, orthognathic surgery, or otolaryngological surgery, to correct a deformity, congenital abnormality or the physical effect of a medical condition, illness or trauma;
  - (i) mammoplasty to correct a deformity, congenital abnormality or the physical effect of a medical condition, illness or trauma;
  - (j) genioplasty to correct a deformity, congenital abnormality or the physical effect of a medical condition, illness or trauma;
  - (k) rhinoplasty to correct a deformity, congenital abnormality or the physical effect of a medical condition, illness or trauma.
- (2) In this section—

***skin tag*** means a polypoid outgrowth of both epidermis and dermal fibrovascular tissue.

## **Part 2D**                      **Disclosure of information for school health programs**

### **12G**    **Prescribed information for school health programs—Act, s 213AD**

For section 213AD(1) of the Act, the following information about a student is prescribed—

- (a) the sex of the student;
- (b) the school's class or group to which the student belongs;
- (c) the language spoken at home by the student;
- (d) whether the student identifies as being an Aboriginal or Torres Strait Islander person.

## **Part 3**                      **Perinatal statistics**

### **13**    **Notifications about perinatal statistics—Act, s 217**

For section 217 of the Act, a notification must be given within 35 days after the day of the delivery.

### **14**    **Prescribed agreements—Act, s 226(1)(a)(i)(B)**

Each agreement mentioned in schedule 3, part 2 is prescribed for section 226(1)(a)(i)(B) of the Act.

## **Part 4**                      **Maternal death statistics**

### **14A**    **Notifications about maternal death statistics—Act, s 228F**

For section 228F(2) of the Act, a notification must be given within 60 days after the health professional becomes aware of the death.

*Note—*

The approved form for the notification is available on the department's website.

**14B Prescribed agreements—Act, s 228O(1)(a)(i)(B)**

Each agreement mentioned in schedule 3, part 3 is prescribed for section 228O(1)(a)(i)(B) of the Act.

## **Part 5 Cancer notifications**

**15 Types of skin cancer and non-invasive carcinoma—Act, s 229, definition *cancer***

For paragraph (b) of the definition *cancer* in section 229 of the Act, the following types of skin cancer and non-invasive carcinoma are prescribed—

- (a) basal cell carcinoma of the skin;
- (b) squamous cell carcinoma of the skin;
- (c) benign neoplasm, other than a central nervous system or brain tumour.

**15A Prescribed person—Act, s 232**

For section 232(1) of the Act, the Hospital and Health Service established under the *Hospital and Health Boards Act 2011*, section 17 and assigned the name Metro South is prescribed.

**16 Notifications about cancer—Act, s 234(1)(b) and (3)**

- (1) For section 234(1)(b) of the Act, a notification must be given within 30 days after the pathological examination.
- (2) For section 234(3) of the Act, a notification must be given within 30 days after the separation or cessation.

**17 Prescribed agreements—Act, s 244(1)(a)(i)(B)**

Each agreement mentioned in schedule 3, part 4 is prescribed for section 244(1)(a)(i)(B) of the Act.

## **Part 6 Pap Smear Register**

**18 Clinical information—Act, s 251, definition *clinical information***

- (1) For paragraph (b) of the definition *clinical information*, in section 251 of the Act, the following information about a woman is prescribed—
  - (a) the dates and results of any vaginal vault smear tests for the woman;
  - (b) whether a Pap smear, vaginal vault smear or histological sample was obtained from the woman;
  - (c) the provider details of the provider who performed the procedure to obtain the Pap smear, vaginal vault smear or histological sample;
  - (d) the number used by the pathology laboratory to identify the provider's request for the testing of the Pap smear, vaginal vault smear or histological sample;
  - (e) the code used by the pathology laboratory to identify the woman;
  - (f) the accession code for the Pap smear, vaginal vault smear or histological sample;
  - (g) any recommendation code for the Pap smear test or vaginal vault smear test;
  - (h) the date the final result of the Pap smear test, vaginal vault smear test or histology test is given to the provider, whether or not preliminary results have also been given to the provider.
- (2) In this section—

***accession code***, for a Pap smear, vaginal vault smear or histological sample, means a code used by a pathology laboratory to identify the Pap smear, vaginal vault smear or histological sample.

***provider details***, of a provider, means—

- (a) if the provider is a medical practitioner—the provider’s name, postal address and provider number; or
- (b) if the provider is not a medical practitioner—the provider’s name and postal address.

***provider number***, of a provider, means the number that is allocated by the Health Insurance Commission to the provider under the *Health Insurance Act 1973* (Cwlth) and identifies the provider and the places where the provider practises his or her profession.

***recommendation code***, for a Pap smear test or vaginal vault smear test, means a code used by a pathology laboratory to identify any recommendation made to a provider after testing the Pap smear or vaginal vault smear.

***vaginal vault smear*** means the cells scraped from the top of the vagina of a woman who has had her cervix removed, for detecting whether the woman has had a recurrence of squamous intraepithelial abnormalities of her vaginal vault.

***vaginal vault smear test*** means the process for testing a vaginal vault smear, to detect the recurrence of squamous intraepithelial abnormalities of the vaginal vault.

## **Part 6A                      Water quality**

### **Division 1                      Preliminary**

#### **18AA Purpose of pt 6A**

This part prescribes standards for the quality of drinking water and particular types of recycled water.

*Note—*

The provisions of this part complement provisions of the *Water Supply (Safety and Reliability) Act 2008*. If a water service provider fails to comply with a provision of this part, the water service provider may be liable to a penalty under that Act.

## **18AB Definitions for pt 6A and schs 3A–3E**

In this part and schedules 3A to 3E—

***chlorine residual*** means the amount of free chlorine remaining in water at the point of supply of the water to the water user.

***class A+ recycled water*** means recycled water intended to be supplied on the basis that it meets the standards prescribed under section 18AE for the quality of class A+ recycled water.

***class A recycled water*** means recycled water intended to be supplied on the basis that it meets the standards prescribed under section 18AF for the quality of class A recycled water.

***class B recycled water*** means recycled water intended to be supplied on the basis that it meets the standards prescribed under section 18AF for the quality of class B recycled water.

***class C recycled water*** means recycled water intended to be supplied on the basis that it meets the standards prescribed under section 18AF for the quality of class C recycled water.

***class D recycled water*** means recycled water intended to be supplied on the basis that it meets the standards prescribed under section 18AF for the quality of class D recycled water.

***drinking water service*** see the *Water Supply (Safety and Reliability) Act 2008*, schedule 3.

***dual reticulation scheme*** means a system of pipes supplying water to a water user for a domestic use, that allows for drinking water and recycled water to be supplied from separate pipes at the same time, but does not include a system of pipes supplying recycled water to a water user for a commercial, industrial or agricultural use.



---

*free chlorine* means chlorine in water that is not combined with any other chemical compound.

*minimally processed food crop* means a crop for a food product that—

- (a) may be eaten raw; or
- (b) will be subjected to a minimal food process only.

*Examples of a minimal food process—*

- washing
- cutting
- peeling
- packaging

*recycled water* means sewage or effluent sourced from a service provider's sewerage, that is intended to be reused.

*reused* see the *Water Supply (Safety and Reliability) Act 2008*, schedule 3.

*service provider* see the *Water Supply (Safety and Reliability) Act 2008*, schedule 3.

## **Division 2                      Standards for water quality—Act, s 461(2)**

### **18AC Drinking water**

The following are standards for the quality of drinking water—

- (a) samples of the drinking water must be taken at the frequency stated in schedule 3A, column 2;
- (b) each sample taken under paragraph (a) must be tested for the factor stated in schedule 3A, column 1;
- (c) the value of the factor under paragraph (b) must not be more than the value stated in schedule 3A, column 3;
- (d) if in any sample taken, the value of the factor under paragraph (b) is more than the value stated in

[s 18AD]

---

- schedule 3A, column 3 for the factor—a follow-up sample must be taken and tested for the factor;
- (e) if the quality of the drinking water has been monitored for at least 12 months—
    - (i) the value (the *annual value*) of the factor in the samples taken under paragraph (a) during the preceding 12 month period must be assessed monthly; and
    - (ii) the annual value of the factor must not be more than the value stated in schedule 3A, column 4 for the factor.

### **18AD Recycled water supplied to augment a supply of drinking water**

- (1) The following are standards for the quality of recycled water that is intended to be supplied to augment a supply of drinking water—
  - (a) samples of the recycled water must be taken and tested for the factors stated in schedule 3B, column 1;
  - (b) unless under an approved recycled water management plan relating to the recycled water a factor does not need to be monitored—the value of each factor in the samples must not be more than the value stated in schedule 3B, parts 1 and 2, column 2 for the factor;
  - (c) if in any sample taken, the value of a factor under paragraph (b) is more than the value stated in schedule 3B, parts 1 and 2, column 2 for the factor—an assessment of the risks to the health of the public from the quality of the recycled water must be carried out;
  - (d) the recycled water must be supplied into an aquifer, lake, watercourse or wetlands, or a dam on a watercourse, and stored under conditions that allow for sufficient management of any risk to the health of the public from the recycled water quality.
- (2) In this section—

***approved recycled water management plan*** means a recycled water management plan approved under the *Water Supply (Safety and Reliability) Act 2008*, schedule 3.

### **18AE Class A+ recycled water**

The following are standards for the quality of class A+ recycled water—

- (a) samples of the recycled water must be taken at the frequency stated in schedule 3C, column 2;
- (b) each sample taken under paragraph (a) must be tested for the factors stated in schedule 3C, column 1;
- (c) if in any sample taken, the value of a factor under paragraph (b) is the value stated in schedule 3C, column 3, paragraph (a) for the factor—a follow-up sample must be taken and tested for the factor;
- (d) the value of each factor in the follow-up samples taken under paragraph (c) must be the value stated in schedule 3C, column 3, paragraph (b) for the factor;
- (e) if the quality of the recycled water has been monitored for at least 12 months—
  - (i) the value (the ***annual value***) of each factor in the samples taken under paragraph (a) during the preceding 12 month period must be assessed monthly; and
  - (ii) the annual value of the factor must be the value stated in schedule 3C, column 4 for the factor.

### **18AF Class A, B, C or D recycled water**

The following are standards for the quality of class A, B, C or D recycled water—

- (a) samples of the recycled water stated in schedule 3D, column 1 must be taken at the frequency stated in column 3 of the schedule;

[s 18AG]

---

- (b) each sample taken under paragraph (a) must be tested for the factors stated in schedule 3D, column 2;
- (c) if in any sample taken, the value of a factor under paragraph (b) is the value stated in schedule 3D, column 4, paragraph (a) for the factor—a follow-up sample must be taken and tested for the factor;
- (d) the value of each factor in the follow-up samples taken under paragraph (c) must be the value stated in schedule 3D, column 4, paragraph (b) for the factor;
- (e) if the quality of the recycled water has been monitored for at least 12 months—
  - (i) the value (the *annual value*) of each factor in the samples taken under paragraph (a) during the preceding 12 month period must be assessed monthly; and
  - (ii) the annual value of the factor must be the value stated in schedule 3D, column 5 for the factor.

### **18AG Recycled water for irrigation of minimally processed food crops**

The standards for the quality of recycled water supplied for irrigating minimally processed food crops are the classes of recycled water stated in schedule 3E, column 3 for the types of crops and methods of irrigation stated in columns 1 and 2 of the schedule.

### **18AH Recycled water supplied for a dual reticulation scheme**

The standard for the quality of recycled water supplied for a dual reticulation scheme is class A+ recycled water.

---

## Part 7                      Miscellaneous

### 18A    **Paint—Act, s 60**

For the Act, section 60(2), definition *standard*, the prescribed part of the Standard for the Uniform Scheduling of Drugs and Poisons dealing with paint is appendix I (Uniform paint standard).

### 19        **Emergency officers (general)—Act, s 333(1)(e)**

- (1) For section 333(1)(e) of the Act, an ambulance officer is a prescribed person.
- (2) In this section—  
*ambulance officer* see the *Ambulance Service Act 1991*, schedule.

### 20        **Human research ethics committee—Act, sch 2, definition *human research ethics committee***

- (1) For the definition *human research ethics committee* in schedule 2 of the Act, the requirements are stated in the National Statement on Ethical Conduct in Human Research 2007, issued by the NHMRC in 2007, as in force from time to time.

*Editor's note—*

A copy of the document is available on the website of the NHMRC.

- (2) In this section—  
*NHMRC* means the National Health and Medical Research Council established under the *National Health and Medical Research Council Act 1992* (Cwlth).

**20A Prescribed training for indemnity conditions—Act, s 454G**

- (1) The prescribed training for section 454G of the Act is training that—
  - (a) is approved by the chief health officer under subsection (2); and
  - (b) includes information about the following—
    - (i) the regulatory environment for control of asbestos risks in Queensland;
    - (ii) asbestos products and likely uses in domestic settings;
    - (iii) health risks of exposure to asbestos;
    - (iv) assessment of health risks and risk control measures;
    - (v) the application of regulatory measures under the Act to control asbestos risk.
- (2) For the purpose of approving training under subsection (1)(a), the chief health officer may have regard to any relevant matter including—
  - (a) the content and quality of the curriculum, including its relevance to the powers and functions of an authorised person; and
  - (b) the qualifications, knowledge and experience of the person who is to provide the training.

## **Part 8 Transitional provisions**

### **21 Transitional asbestos removal licence or certificate**

- (1) A reference in section 2D to a class A asbestos removal licence under the *Work Health and Safety Regulation 2011* includes a reference to a transitional class A asbestos removal

licence defined in the *Work Health and Safety Regulation 2011*, section 744 that is in effect.

- (2) A reference in section 2E to a certificate under the section that is in effect includes a reference to a transitional class B asbestos removal licence defined in the *Work Health and Safety Regulation 2011*, section 744 that is in effect.

# Schedule 1      Notifiable conditions

sections 3 to 8

| Column 1<br>Notifiable<br>condition   | Column 2<br>Clinical<br>diagnosis<br>notifiable<br>condition | Column 3<br>Pathologic<br>al<br>diagnosis<br>notifiable<br>condition | Column 4<br>Pathology<br>request<br>notifiable<br>condition | Column 5<br>Provision<br>al<br>diagnosis<br>notifiable<br>condition | Column 6<br>Controlled<br>notifiable<br>condition |
|---|--|--|---|---|---|
| acquired immunodeficiency syndrome (AIDS)   | •  |  |   |   | •   |
| acute flaccid paralysis   | •  |  |   |   |   |
| acute rheumatic fever   | •  |  |   |   |   |
| acute viral hepatitis   |  |  |   | •   |   |
| adverse event following vaccination   | •  |  |   |   |   |
| anthrax   |  | •  | •   |   |   |
| arbovirus infections—   |  |  |   |   |   |
| • alphavirus infections, including Barmah Forest, getah, Ross River and sindbis viruses |  | •  |   |   |   |
| • bunyavirus infections, including gan gan, mapputta, termeil and trubanaman viruses    |  | •  |   |   |   |



| Column 1   | Column 2                                | Column 3                                    | Column 4                               | Column 5                                   | Column 6                        |
|--|---|---|--|--|---------------------------------|
| Notifiable condition   | Clinical diagnosis notifiable condition | Pathological diagnosis notifiable condition | Pathology request notifiable condition | Provisional diagnosis notifiable condition | Controlled notifiable condition |
| <ul style="list-style-type: none"> <li>flavivirus infections, including alfu, Edge Hill, kokobera, Stratford, West Nile/kunjin and other unspecified flaviviruses</li> </ul> |   | •   |  |  |                                 |
| <ul style="list-style-type: none"> <li>any other arbovirus infections</li> </ul>   |   | •   |  |  |                                 |
| Australian bat lyssavirus infection  |   | •   | •                                      |  |                                 |
| Australian bat lyssavirus - potential exposure (bat bite, scratch or mucous membrane exposure)   | •                                       |   |  |  |                                 |
| avian influenza  |   | •   | •                                      | •  | •                               |
| botulism (food-borne)  |   | •   | •                                      |  |                                 |
| botulism (intestinal - adult)  |   | •   | •                                      |  |                                 |
| botulism (intestinal - infantile)  |   | •   | •                                      |  |                                 |
| botulism (wound)   |   | •   |  |  |                                 |
| brucellosis  |   | •   |  |  |                                 |
| campylobacteriosis   |   | •   |  |  |                                 |
| chancroid  |   | •   |  |  |                                 |
| chikungunya  |   | •   |  |  |                                 |

## Schedule 1

| <b>Column 1</b>  | <b>Column 2</b>                                | <b>Column 3</b>                                    | <b>Column 4</b>                               | <b>Column 5</b>                                   | <b>Column 6</b>                        |
|--|--|--|---|---|--|
| <b>Notifiable condition</b>                                | <b>Clinical diagnosis notifiable condition</b> | <b>Pathological diagnosis notifiable condition</b> | <b>Pathology request notifiable condition</b> | <b>Provisional diagnosis notifiable condition</b> | <b>Controlled notifiable condition</b> |
| chlamydia trachomatis infection (anogenital)               |  | •  |   |   |  |
| chlamydia trachomatis infection (lymphogranuloma venereum) |  | •  |   |   |  |
| chlamydia trachomatis infection (non-anogenital)           |  | •  |   |   |  |
| cholera  |  | •  |   |   | •                                      |
| ciguatera poisoning  | •  |  |   |   |  |
| coronaviruses—   |  |  |   |   |  |
| • Middle East respiratory syndrome coronavirus (MERS-CoV)  |  | •  | •   | •   | •                                      |
| • severe acute respiratory syndrome (SARS)                 |  | •  | •   | •   | •                                      |
| Creutzfeldt-Jakob disease                                  |  | •  |   | •   |  |
| cryptosporidiosis  |  | •  |   |   |  |
| dengue   |  | •  |   | •   |  |
| diphtheria (other than toxigenic diphtheria)               |  | •  |   | •   |  |
| diphtheria (toxigenic)                                     |  | •  |   | •   |  |
| donovanosis  |  | •  |   |   |  |

| <b>Column 1</b>                                     | <b>Column 2</b>                                | <b>Column 3</b>                                    | <b>Column 4</b>                               | <b>Column 5</b>                                   | <b>Column 6</b>                        |
|---|--|--|---|---|--|
| <b>Notifiable condition</b>                         | <b>Clinical diagnosis notifiable condition</b> | <b>Pathological diagnosis notifiable condition</b> | <b>Pathology request notifiable condition</b> | <b>Provisional diagnosis notifiable condition</b> | <b>Controlled notifiable condition</b> |
| food-borne or waterborne illness in 2 or more cases | •  |  |   |   |  |
| food-borne or waterborne illness in food handler    | •  |  |   |   |  |
| gonococcal infection (anogenital)                   |  | •  |   |   |  |
| gonococcal infection (non-anogenital)               |  | •  |   |   |  |
| haemolytic uraemic syndrome (HUS)                   | •  | •  |   |   |  |
| haemophilus influenzae type b (invasive) disease    |  | •  |   | •   |  |
| Hendra virus infection                              |  | •  | •   |   |  |
| hepatitis A   |  | •  |   |   |  |
| hepatitis B (acute)                                 |  | •  |   |   |  |
| hepatitis B (chronic)                               |  | •  |   |   |  |
| hepatitis B (not otherwise specified)               |  | •  |   |   |  |
| hepatitis C   |  | •  |   |   | •                                      |
| hepatitis D   |  | •  |   |   |  |
| hepatitis E   |  | •  |   |   |  |
| hepatitis (other)                                   |  | •  |   |   |  |
| human immunodeficiency virus infection (HIV)        |  | •  |   |   | •                                      |

## Schedule 1

| <b>Column 1</b>  | <b>Column 2</b>                                | <b>Column 3</b>                                    | <b>Column 4</b>                               | <b>Column 5</b>                                   | <b>Column 6</b>                        |
|--|--|--|---|---|--|
| <b>Notifiable condition</b>  | <b>Clinical diagnosis notifiable condition</b> | <b>Pathological diagnosis notifiable condition</b> | <b>Pathology request notifiable condition</b> | <b>Provisional diagnosis notifiable condition</b> | <b>Controlled notifiable condition</b> |
| influenza  |  | •  |   |   | •                                      |
| invasive group A streptococcal infection                                       |  | •  |   |   |  |
| Japanese encephalitis  |  | •  | •   |   |  |
| lead exposure (notifiable) (blood lead level of 5 µg/dL (0.24 µmol/L) or more) |  | •  |   |   |  |
| legionellosis  |  | •  |   |   |  |
| leprosy (Hansen's disease)   |  | •  |   |   |  |
| leptospirosis  |  | •  |   |   |  |
| listeriosis  |  | •  |   |   |  |
| lyssavirus (unspecified)   |  | •  | •   |   |  |
| malaria  |  | •  |   |   |  |
| measles  |  | •  |   | •   | •                                      |
| melioidosis  |  | •  |   |   |  |
| meningococcal disease (invasive)   |  | •  |   | •   |  |
| mumps  |  | •  |   |   |  |
| Murray Valley encephalitis   |  | •  | •   |   |  |
| non tuberculous mycobacterial disease  |  | •  |   |   |  |

| Column 1<br>Notifiable condition   | Column 2<br>Clinical diagnosis notifiable condition | Column 3<br>Pathological diagnosis notifiable condition | Column 4<br>Pathology request notifiable condition | Column 5<br>Provisional diagnosis notifiable condition | Column 6<br>Controlled notifiable condition |
|--|---|---|--|--|---|
| paratyphoid  |   | •   |  |  | •   |
| pertussis  | •   | •   |  |  |   |
| plague   |   | •   | •  |  | •   |
| pneumococcal disease (invasive)  |   | •   |  |  |   |
| poliomyelitis infection  |   | •   | •  |  |   |
| psittacosis (ornithosis)   |   | •   |  |  |   |
| Q fever  |   | •   |  |  |   |
| rabies   |   | •   | •  |  | •   |
| rotavirus infection  |   | •   |  |  |   |
| rubella, including congenital rubella  |   | •   |  |  |   |
| salmonellosis  |   | •   |  |  |   |
| shiga toxin and vero toxin producing <i>escherichia coli</i> infection STEC/VTEC |   | •   |  |  |   |
| shigellosis  |   | •   |  |  |   |
| smallpox   |   | •   | •  | •  | •   |
| syphilis, including congenital syphilis  |   | •   |  |  | •   |
| tetanus  | •   | •   |  |  |   |
| tuberculosis   |   | •   |  | •  | •   |

## Schedule 1

| <b>Column 1</b>   | <b>Column 2</b>                                | <b>Column 3</b>                                    | <b>Column 4</b>                               | <b>Column 5</b>                                   | <b>Column 6</b>                        |
|---|--|--|---|---|--|
| <b>Notifiable condition</b>   | <b>Clinical diagnosis notifiable condition</b> | <b>Pathological diagnosis notifiable condition</b> | <b>Pathology request notifiable condition</b> | <b>Provisional diagnosis notifiable condition</b> | <b>Controlled notifiable condition</b> |
| tularaemia  |  | •  | •   |   |  |
| typhoid   |  | •  |   |   | •                                      |
| varicella - zoster virus infection (chickenpox, shingles or unspecified)          |  | •  |   |   |  |
| viral haemorrhagic fevers (Crimean-Congo, Ebola, Lassa fever and Marburg viruses) |  | •  | •   | •   | •                                      |
| yellow fever  |  | •  | •   |   | •                                      |
| yersiniosis   |  | •  |   |   |  |
| zika virus  |  | •  |   |   |  |

---

## Schedule 2      Immediate notifications

sections 9 to 12

acute flaccid paralysis

anthrax

Australian bat lyssavirus infection

Australian bat lyssavirus - potential exposure (i.e. bat bite, scratch or mucous membrane exposure)

avian influenza

botulism (food-borne)

botulism (intestinal - adult)

botulism (intestinal - infantile)

cholera

ciguatera poisoning

dengue

diphtheria (toxigenic)

flavivirus infections, including alfuy, Edge Hill, Japanese encephalitis, kokobera, Murray Valley encephalitis, Stratford, West Nile/kunjn and other unspecified flaviviruses (excluding dengue and yellow fever)

food-borne or waterborne illness in 2 or more cases

food-borne or waterborne illness in food handler

haemolytic uraemic syndrome (HUS)

haemophilus influenzae type b (invasive) disease

Hendra virus infection

hepatitis A

legionellosis

measles

meningococcal disease (invasive)

paratyphoid

plague

poliomyelitis infection

rabies

severe acute respiratory syndrome (SARS)

smallpox

tularaemia

typhoid

viral haemorrhagic fevers (Crimean-Congo, Ebola, Lassa fever and Marburg viruses)

yellow fever



## **Schedule 2A     Contagious conditions**

sections 12B and 12E

### **Part 1                     Contagious conditions**

diphtheria  
enterovirus 71 neurological disease  
gastroenteritis illness  
haemophilus influenzae type b (invasive) disease  
hepatitis A  
human influenza with pandemic potential  
measles  
meningococcal disease (invasive)  
paratyphoid  
pertussis  
poliomyelitis infection  
rubella  
tuberculosis  
typhoid  
varicella - zoster virus infection (chickenpox)

## Part 2

# Prescribed period for contagious condition for child suspected of having condition

| Contagious condition                | Prescribed period for a contagious condition for a child suspected of having the condition  |  |
|-------------------------------------|---|--|
|                                     | Start of period   | End of period  |
| diphtheria                          | <p>the earlier of the following—</p> <p>(a) onset of symptoms;</p> <p>(b) relevant contact of the child with a person infected with the condition</p> | <p>either—</p> <p>(a) if the child has had symptoms—the treating doctor confirms 2 negative throat swabs have been taken from the child—</p> <p>(i) the first swab taken at least 24 hours after the child finishes a course of an appropriate antibiotic; and</p> <p>(ii) the second swab taken at least 24 hours after the first swab; or</p> <p>(b) otherwise—the treating doctor confirms 1 negative throat swab has been taken from the child</p> |
| enterovirus 71 neurological disease | onset of symptoms   | the treating doctor confirms the virus is no longer present in the child's bowel motions   |
| gastroenteritis illness             | onset of symptoms   | the child has no symptoms and has not had a loose bowel motion for at least 24 hours or, if a laboratory test confirms a norovirus, for at least 48 hours  |

| <b>Contagious condition</b>                      | <b>Prescribed period for a contagious condition for a child suspected of having the condition</b>   |   |
|--|---|---|
|  | <b>Start of period</b>  | <b>End of period</b>  |
| haemophilus influenzae type b (invasive) disease | onset of symptoms   | <p>the earlier of the following—</p> <ul style="list-style-type: none"> <li>(a) the treating doctor confirms the child is not infectious after the child has taken 4 days of an appropriate antibiotic;</li> <li>(b) the chief executive advises a parent of the child that the chief executive is satisfied the risk of the child transmitting the contagious condition is low, having regard to— <ul style="list-style-type: none"> <li>(i) the way the contagious condition is transmitted; and</li> <li>(ii) the nature of the environment at the child’s school, education and care service or QEC approved service</li> </ul> </li> </ul> |
| hepatitis A                                      | <p>the earlier of the following—</p> <ul style="list-style-type: none"> <li>(a) onset of symptoms;</li> <li>(b) the child is diagnosed</li> </ul> | <p>the earlier of the following—</p> <ul style="list-style-type: none"> <li>(a) the treating doctor confirms the child is not infectious, but not earlier than 7 days after the onset of jaundice;</li> <li>(b) the chief executive advises a parent of the child that the chief executive is satisfied the risk of the child transmitting the contagious condition is low, having regard to— <ul style="list-style-type: none"> <li>(i) the way the contagious condition is transmitted; and</li> <li>(ii) the nature of the environment at the child’s school, education and care service or QEC approved service</li> </ul> </li> </ul>      |

| <b>Contagious condition</b>             | <b>Prescribed period for a contagious condition for a child suspected of having the condition</b>   |   |
|---|---|---|
|   | <b>Start of period</b>  | <b>End of period</b>  |
| human influenza with pandemic potential | <p>the earlier of the following—</p> <p>(a) onset of symptoms;</p> <p>(b) relevant contact of the child with a person infected with the condition</p> | <p>either—</p> <p>(a) if the child has had symptoms—the treating doctor confirms the child is not infectious but not earlier than 5 days after the onset of the symptoms; or</p> <p>(b) otherwise—7 days after the child’s last contact with a person who is, or is suspected of being, infected with the condition</p>   |
| measles                                 | <p>the earlier of the following—</p> <p>(a) onset of symptoms;</p> <p>(b) relevant contact of the child with a person infected with the condition</p> | <p>either—</p> <p>(a) if the child has had symptoms—the treating doctor confirms the child is not infectious, but not earlier than 4 days after the onset of the rash caused by the condition; or</p> <p>(b) otherwise—the earliest of the following—</p> <p>(i) if the child is vaccinated for measles within 72 hours of the relevant contact for the child—the child is vaccinated;</p> <p>(ii) if the child receives normal human immunoglobulin (<i>NHIG</i>) within 7 days after the relevant contact for the child—the child receives <i>NHIG</i>;</p> <p>(iii) 18 days after the child’s last contact with a person who is, or is suspected of being, infected with the condition</p> |
| meningococcal disease (invasive)        | onset of symptoms   | the treating doctor confirms the child is not infectious after the child has completed at least 24 hours of a course of an appropriate antibiotic   |

| <b>Contagious condition</b> | <b>Prescribed period for a contagious condition for a child suspected of having the condition</b>   |   |
|-----------------------------|---|---|
|                             | <b>Start of period</b>  | <b>End of period</b>  |
| paratyphoid                 | <p>the earliest of the following—</p> <p>(a) onset of symptoms;</p> <p>(b) the child is diagnosed;</p> <p>(c) relevant contact of the child with a person infected with the condition</p> | <p>either—</p> <p>(a) if the child has had symptoms or is diagnosed—the treating doctor confirms the child is not infectious after—</p> <p>(i) the child has completed a course of an appropriate antibiotic; and</p> <p>(ii) at least 48 hours after the course of antibiotics, the child has a negative stool specimen; and</p> <p>(iii) at least 1 week after the negative stool specimen, the child has another negative stool specimen; or</p> <p>(b) otherwise—the earlier of the following—</p> <p>(i) the treating doctor confirms the child is not infectious after the child has 2 negative stool specimens at least 24 hours apart;</p> <p>(ii) the chief executive advises a parent of the child that the chief executive is satisfied the risk of the child transmitting the contagious condition is low, having regard to—</p> <p>(A) the way the contagious condition is transmitted; and</p> <p>(B) the nature of the environment at the child’s school, education and care service or QEC approved service</p> |

| <b>Contagious condition</b> | <b>Prescribed period for a contagious condition for a child suspected of having the condition</b>   |   |
|-----------------------------|---|---|
|                             | <b>Start of period</b>  | <b>End of period</b>  |
| pertussis                   | <p>the earlier of the following—</p> <p>(a) onset of symptoms;</p> <p>(b) relevant contact of the child with a person infected with the condition</p> | <p>either—</p> <p>(a) if the child has had symptoms—the treating doctor confirms the child is not infectious, but not earlier than—</p> <p>(i) 5 days after the child starts a course of an appropriate antibiotic; or</p> <p>(ii) if the child has an onset of paroxysmal coughing caused by the condition—14 days after the onset of the coughing; or</p> <p>(iii) otherwise—21 days after the onset of coughing; or</p> <p>(b) otherwise—the earlier of the following—</p> <p>(i) the treating doctor confirms the child is not infectious but not earlier than 14 days after the relevant contact;</p> <p>(ii) the chief executive advises a parent of the child that the chief executive is satisfied the risk of the child transmitting the contagious condition is low, having regard to—</p> <p>(A) the way the contagious condition is transmitted; and</p> <p>(B) the nature of the environment at the child’s school, education and care service or QEC approved service</p> |

| <b>Contagious condition</b> | <b>Prescribed period for a contagious condition for a child suspected of having the condition</b>  |  |
|-----------------------------|--|--|
|                             | <b>Start of period</b>   | <b>End of period</b>   |
| poliomyelitis infection     | <p>the earliest of the following—</p> <ul style="list-style-type: none"> <li>(a) onset of symptoms;</li> <li>(b) the child is diagnosed;</li> <li>(c) relevant contact of the child with a person infected with the condition</li> </ul> | <p>the chief executive advises a parent of the child that the chief executive is satisfied the risk of the child transmitting the contagious condition is low, having regard to—</p> <ul style="list-style-type: none"> <li>(a) the way the contagious condition is transmitted; and</li> <li>(b) the nature of the environment at the child's school, education and care service or QEC approved service</li> </ul> |
| rubella                     | onset of symptoms  | 4 days after the onset of the rash caused by the condition   |
| tuberculosis                | onset of symptoms  | the treating doctor confirms the child is not infectious   |

| <b>Contagious condition</b>                     | <b>Prescribed period for a contagious condition for a child suspected of having the condition</b>  |   |
|---|--|---|
|   | <b>Start of period</b>   | <b>End of period</b>  |
| typhoid   | the earliest of the following—<br>(a) onset of symptoms;<br>(b) the child is diagnosed;<br>(c) relevant contact of the child with a person infected with the condition | either—<br>(a) if the child has had symptoms or been diagnosed—the treating doctor confirms the child is not infectious after—<br>(i) the child has completed a course of an appropriate antibiotic; and<br>(ii) at least 48 hours after the course of antibiotics, the child has a negative stool specimen; and<br>(iii) at least 1 week after the negative stool specimen, the child has another negative stool specimen;<br>or<br>(b) otherwise—the earlier of the following—<br>(i) the treating doctor confirms the child is not infectious after the child has 2 negative stool specimens at least 24 hours apart;<br>(ii) the chief executive advises a parent of the child that the chief executive is satisfied the risk of the child transmitting the contagious condition is low, having regard to—<br>(A) the way the contagious condition is transmitted; and<br>(B) the nature of the environment at the child’s school, education and care service or QEC approved service |
| varicella - zoster virus infection (chickenpox) | onset of symptoms  | all blisters caused by the condition have dried, but not earlier than 5 days after the onset of symptoms  |



## Part 3 Prescribed period for contagious condition for child suspected of not being vaccinated

| Contagious condition | Prescribed period for a contagious condition for a child suspected of not being vaccinated  |  |
|----------------------|---|--|
|                      | Start of period   | End of period  |
| measles              | the chief executive gives a direction there is an outbreak of the condition at the school, education and care service or QEC approved service attended by the child | <p>the earlier of the following—</p> <ul style="list-style-type: none"> <li>(a) if the child is not vaccinated—the chief executive gives a direction that the outbreak of the condition at the school, education and care service or QEC approved service is over;</li> <li>(b) if the child is vaccinated during the outbreak—the chief executive advises a parent of the child that the chief executive is satisfied the risk of the child contracting the contagious condition is low, having regard to— <ul style="list-style-type: none"> <li>(i) the way the contagious condition is transmitted; and</li> <li>(ii) the nature of the environment at the child’s school, education and care service or QEC approved service</li> </ul> </li> </ul> |

**Contagious condition****Prescribed period for a contagious condition for a child suspected of not being vaccinated****Start of period**

the chief executive gives a direction there is an outbreak of the condition in the community, if there is a risk of children and staff at the school, education and care service or QEC approved service attended by the child contracting the condition

**End of period**

the chief executive advises a parent of the child that the chief executive is satisfied the risk of the child contracting the contagious condition is low, having regard to—

- (a) the way the contagious condition is transmitted; and
- (b) the nature of the environment at the child's school, education and care service or QEC approved service

## Part 4 Definitions

### 1 Definitions for sch 2A

In this schedule—

*confirms* means gives written confirmation.

*diagnosed*, for a child with a contagious condition, means a doctor or laboratory test confirms the child has the condition.

*relevant contact*, of a child for a contagious condition, means—

- (a) for diphtheria—the child's first close contact with a person (the *infected person*) who is, or is suspected of being, infected with the condition during the period—
  - (i) starting 7 days before the onset of symptoms in the infected person; and
  - (ii) ending when the treating doctor confirms 2 negative throat swabs have been taken from the person at the following times—

- (A) the first swab taken at least 24 hours after the person finishes a course of an appropriate antibiotic;
  - (B) the second swab taken at least 24 hours after the first swab; or
- (b) for a contagious condition other than diphtheria—contact with a person who has been diagnosed with the condition while the person is infectious for the condition.

*suspected* means suspected under chapter 5 of the Act.

*symptoms*, for a contagious condition, means symptoms of the condition.

## **Schedule 2B    Vaccine preventable conditions**

section 12D

diphtheria  
haemophilus influenzae type b (invasive) disease  
hepatitis B  
measles  
meningococcal C  
mumps  
pertussis  
poliomyelitis infection  
pneumococcal disease (invasive)  
rotavirus infection  
rubella  
tetanus  
varicella - zoster virus infection (chickenpox)

---

## **Schedule 3      Agreements**

sections 12AA, 14, 14B and 17

### **Part 1                      Confidentiality of information relating to notifiable conditions**

#### **Division 1                  Agreements with Commonwealth, State or entity**

- The agreement dated 5 May 2008 called, ‘Confidentiality agreement between State of Queensland acting through Queensland Health and the University of Melbourne’.
- The agreement called ‘ARF/RHD Register Service Agreement’ between Queensland and the Menzies School of Health Research.

#### **Division 2                  Agreements with State entity**

- The agreement called ‘Memorandum of Understanding Exchange of information regarding Notifiable Conditions’ between Queensland acting through the Department of Natural Resources and Mines and Queensland acting through Queensland Health.
- The agreement called ‘Memorandum of Understanding Exchange of information regarding Notifiable Conditions’ between Queensland acting through Queensland Treasury and Queensland acting through Queensland Health.
- The agreement called ‘Memorandum of Understanding for disclosure of confidential information between State of Queensland acting through Queensland Health and Queensland Family and Child Commission’.

## **Part 2    Confidentiality of information relating to perinatal statistics**

- National Health Information Agreement between the Commonwealth, State and Territory health, statistical and national authorities, commenced on 1 October 2013
- Intergovernmental Agreement on Federal Financial Relations, the schedules and any agreements under the schedules, as amended from time to time, between the Commonwealth of Australia and the States and Territories of Australia, commenced 1 January 2009

## **Part 3    Confidentiality of information relating to maternal death statistics**

- National Health Information Agreement between the Commonwealth, State and Territory health, statistical and national authorities, commenced on 1 October 2013
- Intergovernmental Agreement on Federal Financial Relations, the schedules and any agreements under the schedules, as amended from time to time, between the Commonwealth of Australia and the States and Territories of Australia, commenced 1 January 2009

## **Part 4    Confidentiality of information relating to cancer notifications**

- National Health Information Agreement between the Commonwealth, State and Territory health, statistical and national authorities, commenced on 1 October 2013

## Schedule 3A Standards for quality of drinking water

section 18AC

| Column 1<br>Factor   | Column 2<br>Frequency of sampling  | Column 3<br>Value | Column 4<br>Annual value  |
|--|--|-------------------|---|
| <i>Escherichia coli</i> —in the reticulation system for the drinking water service | (a) if the drinking water service supplies drinking water to more than 100,000 people— <ul style="list-style-type: none"> <li>(i) 6 samples a week; and</li> <li>(ii) 1 additional sample a month for each 10,000 people by which the number of people supplied exceeds 100,000;</li> </ul> or                     | nil cfu/100mL     | nil cfu/100mL found in 98% of the samples taken for a 12 month period |
|  | (b) if the drinking water service supplies drinking water to more than 5,000 but not more than 100,000 people— <ul style="list-style-type: none"> <li>(i) 1 sample a week; and</li> <li>(ii) 1 additional sample a month for each 5,000 people by which the number of people supplied exceeds 5,000; or</li> </ul> | nil cfu/100mL     | nil cfu/100mL found in 98% of the samples taken for a 12 month period |

## Schedule 3A

| <b>Column 1</b><br><b>Factor</b>  | <b>Column 2</b><br><b>Frequency of sampling</b>   | <b>Column 3</b><br><b>Value</b> | <b>Column 4</b><br><b>Annual value</b>                                |
|---|---|---------------------------------|---|
|   | (c) if the drinking water service supplies drinking water to more than 1,000 but not more than 5,000 people—1 sample a week; or | nil cfu/100mL                   | nil cfu/100mL found in 98% of the samples taken for a 12 month period |
|   | (d) if the drinking water service supplies drinking water to 1,000 people or less—1 sample a month                              | nil cfu/100mL                   | nil cfu/100mL found in 98% of the samples taken for a 12 month period |
| Fluoride concentration of fluoridated water at a point where the fluoridated water has mixed to a consistent fluoride concentration | Daily   | 1.5mg/L                         | 1.5mg/L   |



## Schedule 3B Standards for quality of recycled water supplied to augment a supply of drinking water

section 18AD

### Part 1 Microorganisms

| Column 1<br>Factor                          | Column 2<br>Value |
|---|-------------------|
| <b>Microorganisms</b>                       |                   |
| <i>Clostridium perfringens</i>              | nil cfu/100mL     |
| <i>Escherichia coli</i>                     | nil cfu/100mL     |
| F-RNA bacteriophages                        | nil pfu/100mL     |
| <i>Somatic coliphages</i>                   | nil pfu/100mL     |
| Any viral, bacterial or protozoan pathogens | nil detected      |

### Part 2 Chemical compounds

| Column 1<br>Factor                            | Column 2<br>Value<br>(µg/L unless otherwise stated) |
|---|---|
| 4-Acetyl-6-t-butyl-1, 1-dimethylindan         | 7   |
| 6-Acetyl-1, 1, 2, 4, 4, 7-hexamethyltetraline | 4   |

## Schedule 3B

| <b>Column 1</b>                | <b>Column 2</b>   |
|--------------------------------|---|
| <b>Factor</b>                  | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| Acenaphthylene                 | 0.014   |
| Acephate                       | 10  |
| Acetophenone                   | 400   |
| Acetylsalicylic acid (Aspirin) | 29  |
| Acrylamide (2-propenamide)     | 0.2   |
| Alachlor (Lasso)               | 2   |
| Aldicarb                       | 1   |
| Aldicarb sulphone (aldoxycarb) | 7   |
| Aldicarb sulphoxide            | 7   |
| Aldrin                         | 0.3   |
| Alprazolam                     | 0.25  |
| Aluminium                      | 200   |
| Ametryn                        | 50  |
| Amitrole                       | 10  |
| Ammonia                        | 500   |
| Amoxicillin                    | 1.5   |
| Androsterone                   | 14  |
| Anhydroerythromycin A          | 17.5  |
| Anthracene                     | 150   |
| Antimony                       | 3   |
| Antipyrine (Phenazone)         | 1,000   |
| Arsenic                        | 7   |
| Asulam                         | 50  |

| <b>Column 1</b>                        | <b>Column 2</b>   |
|--|---|
| <b>Factor</b>                          | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| Atenolol                               | 25  |
| Atorvastatin                           | 5   |
| Atrazine (total) including metabolites | 40  |
| Azinphos-methyl                        | 3   |
| Azithromycin                           | 3.9   |
| Barium                                 | 700   |
| Benomyl                                | 100   |
| Bentazone                              | 30  |
| Benzene                                | 1   |
| Benzo(a)pyrene                         | 0.01  |
| Benzyl chloride                        | 0.2   |
| Betaxolol                              | 10  |
| Bezafibrate (Benzafibrate)             | 300   |
| Bioresmethrin                          | 100   |
| Bisoprolol                             | 0.63  |
| Bisphenol A                            | 200   |
| Boron                                  | 4,000   |
| Bromacil                               | 300   |
| Bromate                                | 20  |
| Bromide                                | 7,000   |
| Bromine                                | 7,000   |
| Bromoacetic acid                       | 0.35  |
| Bromochloroacetic acid                 | 0.014   |

## Schedule 3B

| <b>Column 1</b>   | <b>Column 2</b>   |
|---|---|
| <b>Factor</b>   | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| Bromochloroacetonitrile   | 0.7   |
| Bromochloromethane  | 40  |
| Bromodichloromethane  | 6   |
| Bromoform   | 100   |
| Bromophos-ethyl   | 10  |
| Bromoxynil  | 30  |
| Butylated hydroxyanisole (3-tert-butyl-4-hydroxy anisole) (BHA) | 1,800   |
| Butylated hydroxytoluene (2,6-Di-tert-Butyl-p-Cresol) (BHT)     | 1,000   |
| 2-Chlorophenol  | 300   |
| 4-Chlorophenol  | 10  |
| 4-Cumylphenol   | 0.35  |
| Cadmium   | 2   |
| Caffeine  | 0.35  |
| Carazolol   | 0.35  |
| Carbamazepine   | 100   |
| Carbaryl  | 30  |
| Carbendazim   | 100   |
| Carbofuran  | 10  |
| Carbon tetrachloride  | 3   |
| Carbophenothion   | 0.5   |
| Carboxin  | 300   |
| [[Carboxymethyl]imino]bis(ethylenenitrilo)]tetra acetic acid    | 5   |
| Cefaclor  | 250   |

| <b>Column 1</b>               | <b>Column 2</b>   |
|-------------------------------|---|
| <b>Factor</b>                 | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| Cephalexin                    | 35  |
| Chloramphenicol               | 175   |
| Chlordane                     | 1   |
| Chlorfenvinphos               | 5   |
| Chlorine                      | 5,000   |
| Chlorine dioxide              | 1,000   |
| Chlorite                      | 300   |
| Chloroacetic acid             | 150   |
| Chlorobenzene                 | 300   |
| Chloroform (Trichloromethane) | 200   |
| Chlorophene                   | 0.35  |
| Chlorotetracycline            | 105   |
| Chlorothalonil                | 30  |
| Chloroxuron                   | 10  |
| Chlorpyrifos                  | 10  |
| Chlorpyrifos methyl           | 10  |
| Chlorpyrifos oxon             | 0.35  |
| Chlorsulfuron                 | 100   |
| Cholesterol                   | 7   |
| Chromium (as Cr(VI))          | 50  |
| Cimetidine                    | 200   |
| Ciproflaxin                   | 250   |
| Citalopram                    | 4   |

## Schedule 3B

| <b>Column 1</b>                            | <b>Column 2</b>   |
|--|---|
| <b>Factor</b>                              | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| Clarithromycin                             | 250   |
| Clenbuterol                                | 15  |
| Clindamycin                                | 300   |
| Clofibric acid                             | 750   |
| Clopyralid                                 | 1,000   |
| Codeine                                    | 50  |
| Copper                                     | 2,000   |
| Coprostanol                                | 0.7   |
| Cotinine                                   | 10  |
| Coumarin                                   | 0.5   |
| Cyanide                                    | 80  |
| Cyanogen chloride (as cyanide)             | 80  |
| Cyclophosphamide                           | 3.5   |
| Cypermethrin                               | 0.5   |
| 1,1 Dichloroethene                         | 30  |
| 1,2 Dichlorobenzene                        | 1,500   |
| 1,2 Dichloroethane                         | 3   |
| 1,2 Dichloroethene                         | 60  |
| 1,4 Dichlorobenzene                        | 40  |
| 1,7-Dimethylxanthine (Paraxanthine)        | 0.7   |
| 2,2-Dichloropropionic acid (DPA) (Dalapon) | 500   |
| 2,4-Dichlorophenol                         | 200   |
| 2,4-Dichlorophenoxyacetic acid (2,4,D)     | 30  |

| <b>Column 1</b>   | <b>Column 2</b>   |
|---|---|
| <b>Factor</b>   | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| 2,4-Dichloropheoxypropionic acid (2,4-DP) (Dichlorprop)                                     | 100   |
| 2,5-Dihydroxybenzoic Acid   | 7   |
| 2,6-Dichlorophenol  | 10  |
| 2,6-Di-tert-butyl-1,4-benzoquinone(2,6-bis(1,1-dimethylethyl)-2,5-Cyclohexadiene-1,4-dione) | 0.014   |
| 2,6-Di-tert-Butylphenol (2,6-bis(1,1-dimethylethyl)phenol)                                  | 2   |
| 2,7-Dichlorodibenzo-p-dioxin (DCDD)   | 0.000016  |
| 3,4-Dichloroaniline   | 0.35  |
| 4,4'-Dichloro-diphenyl-dichloroethylene (DDE)   | 20  |
| 4,4'-Dichloro-diphenyl-trichloroethane (DDT)  | 20  |
| DEET (N,N-diethyltoluamide (NN-diethyl-3-methylbenzamide))                                  | 2,500   |
| Dehydronifedipine   | 20  |
| Demeclocycline  | 300   |
| Demeton-S   | 0.15  |
| Desethyl atrazine   | 40  |
| Desisopropyl atrazine   | 40  |
| Desmethyl citalopram  | 4   |
| Desmethyl diazepam (Nordazepam)   | 3   |
| Di (2-ethylhexyl) phthalate   | 10  |
| Diatrizoate sodium  | 0.35  |
| Diatrizoic acid   | 0.35  |
| Diazepam (Valium)   | 2.5   |
| Diazinon  | 3   |
| Dibromoacetic acid  | 0.014   |

## Schedule 3B

| <b>Column 1</b>                      | <b>Column 2</b>   |
|--------------------------------------|---|
| <b>Factor</b>                        | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| Dibromochloromethane                 | 100   |
| Dibutyltin (DBT)                     | 2   |
| Dicamba                              | 100   |
| Dichlobenil                          | 10  |
| Dichloroacetic acid                  | 100   |
| Dichloroacetonitrile                 | 2   |
| Dichloromethane (Methylene chloride) | 4   |
| Dichlorvos                           | 1   |
| Diclofenac                           | 1.8   |
| Diclofop-methyl                      | 5   |
| Dicofol                              | 3   |
| Dieldrin                             | 0.3   |
| Difenzoquat                          | 100   |
| Diltiazem                            | 60  |
| Dimethoate                           | 50  |
| Di-n-butyl phthalate                 | 35  |
| Diphenamid                           | 300   |
| Dipyrene                             | 525   |
| Diquat                               | 5   |
| Disulfoton                           | 3   |
| Diuron                               | 30  |
| Doxycycline                          | 10.5  |
| 17 $\alpha$ -estradiol               | 0.175   |



| <b>Column 1</b>                         | <b>Column 2</b>   |
|---|---|
| <b>Factor</b>                           | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| 17 $\alpha$ -ethinyl estradiol          | 0.0015  |
| 17 $\beta$ -estradiol                   | 0.175   |
| Enalaprilat                             | 1.3   |
| Endosulfan                              | 30  |
| Endothal                                | 100   |
| Enrofloxacin                            | 22  |
| Epichlorohydrin                         | 0.5   |
| Equilenin                               | 0.030   |
| Equilin                                 | 0.030   |
| Erythromycin                            | 17.5  |
| Estriol                                 | 0.05  |
| Estrone                                 | 0.03  |
| Ethion                                  | 3   |
| Ethoprophos (Mocap)                     | 1   |
| Ethylbenzene                            | 300   |
| Ethyl dipropylthiocarbamate (EPTC)      | 30  |
| Ethylenediamine tetraacetic acid (EDTA) | 250   |
| Ethylene dibromide (EDB)                | 1   |
| Etridiazole                             | 100   |
| Fenamiphos                              | 0.3   |
| Fenarimol                               | 30  |
| Fenchlorphos                            | 30  |
| Fenitrothion                            | 10  |

## Schedule 3B

| <b>Column 1</b>                              | <b>Column 2</b>   |
|--|---|
| <b>Factor</b>                                | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| Fenoprofen                                   | 450   |
| Fenoprop (Silvex) (2,4,5-TP)                 | 10  |
| Fensulfothion                                | 10  |
| Fenthion (fenthion-methyl)                   | 0.5   |
| Fenvalerate                                  | 50  |
| Flamprop-methyl                              | 3   |
| Fluometuron                                  | 50  |
| Fluoride                                     | 1,500   |
| Fluoxetine (Prozac)                          | 10  |
| Fluroxypyr                                   | 700   |
| Formaldehyde                                 | 500   |
| Formothion                                   | 50  |
| Fosamine                                     | 30  |
| Furosemide                                   | 10  |
| Fyrol FR 2 (tri(dichlorisopropyl) phosphate) | 1   |
| Galaxolide                                   | 1,800   |
| Gemfibrozil                                  | 600   |
| Glyphosate                                   | 1,000   |
| 3-Hydroxy carbofuran                         | 0.5   |
| Haloxypop                                    | 1.05  |
| Haloxypop methyl                             | 0.175   |
| Heptachlor and heptachlor epoxide            | 0.3   |
| Hexachlorobutadiene                          | 0.7   |

| <b>Column 1</b>                            | <b>Column 2</b>   |
|--|---|
| <b>Factor</b>                              | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| Hexaflurate                                | 30  |
| Hexazinone                                 | 300   |
| Hydrochlorthiazide                         | 12.5  |
| Ibuprofen                                  | 400   |
| Indomethacin                               | 25  |
| Iodide                                     | 100   |
| Iodine                                     | 60  |
| Iohexol                                    | 720   |
| Iopamidol                                  | 400   |
| Iopromide                                  | 750   |
| Iron                                       | 300   |
| Isophosphamide                             | 3.5   |
| Ketoprofen                                 | 3.5   |
| Lead                                       | 10  |
| Lincomycin                                 | 3,500   |
| Lindane (alpha BHC, beta BHC)              | 20  |
| 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 2   |
| 4-Methylphenol (p-cresol)                  | 600   |
| 5-methyl-1H-benzotriazole                  | 0.007   |
| Maldison (Malathion)                       | 900   |
| Manganese                                  | 500   |
| Mecoprop (MCP)                             | 10  |
| Mercury                                    | 1   |

## Schedule 3B

| <b>Column 1</b>                   | <b>Column 2</b>   |
|-----------------------------------|---|
| <b>Factor</b>                     | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| Mestranol                         | 0.0025  |
| Metformin (1,1-Dimethylbiguanide) | 250   |
| Methidathion                      | 30  |
| Methiocarb                        | 5   |
| Metholmyl                         | 30  |
| Methotrexate                      | 0.005   |
| Methoxychlor                      | 300   |
| Metolachlor                       | 300   |
| Metoprolol                        | 25  |
| Metribuzin                        | 50  |
| Metsulfuron-methyl                | 30  |
| Mevinphos                         | 5   |
| Molinate                          | 5   |
| Molybdenum                        | 50  |
| Monensin                          | 35  |
| Monobutyltin (MBT)                | 0.7   |
| Monochloramine                    | 3,000   |
| Monocrotophos                     | 1   |
| Musk ketone                       | 350   |
| Musk tibetene                     | 0.35  |
| 4-Nitrophenol                     | 30  |
| 4-Nonylphenol (4NP)               | 500   |
| Nadolol                           | 20  |

| <b>Column 1</b>                   | <b>Column 2</b>   |
|-----------------------------------|---|
| <b>Factor</b>                     | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| Naladixic acid                    | 1,000   |
| Naphthalene                       | 70  |
| Napropamide                       | 1,000   |
| Naproxen                          | 220   |
| Nickel                            | 20  |
| Nitralin                          | 500   |
| Nitrate                           | 50,000  |
| Nitrilotriacetic acid (NTA)       | 200   |
| Nitrite                           | 3,000   |
| N-Nitrosodiethylamine (NDEA)      | 0.010   |
| N-Nitrosodimethylamine (NDMA)     | 0.010   |
| N-nitrosomorpholine (NMOR)        | 0.001   |
| Norethindrone                     | 0.250   |
| Norflaxin                         | 400   |
| Norflurazon                       | 50  |
| Octachlorodibenzo-p-dioxin (OCDD) | 0.000016  |
| Oryzalin                          | 300   |
| Oxamyl                            | 100   |
| Oxazepam                          | 15  |
| Oxycodone                         | 10  |
| Oxytetracycline (Terramycin)      | 105   |
| 2-Phenylphenol                    | 1,000   |
| Paracetamol (acetaminophen)       | 175   |

## Schedule 3B

| <b>Column 1</b>                            | <b>Column 2</b>   |
|--|---|
| <b>Factor</b>                              | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| Paraquat                                   | 30  |
| Parathion (ethyl parathion)                | 10  |
| Parathion methyl                           | 100   |
| PCB105 (2,3,3',4,4'-pentachlorobiphenyl)   | 0.000016  |
| PCB118 (2,3',4,4',5-Pentachlorobiphenyl)   | 0.000016  |
| PCB156 (2,3,3',4,4',5-Hexachlorobiphenyl)  | 0.000016  |
| PCB167 (2,4,5,3',4',5'-Hexachlorobiphenyl) | 0.000016  |
| PCB169 (3,4,5,3',4',5'-Hexachlorobiphenyl) | 0.000016  |
| PCB77 (3,3',4,4'-Tetrachlorobiphenyl)      | 0.000016  |
| Pebulate                                   | 30  |
| Pendimethalin                              | 300   |
| Penicillin G                               | 1.5   |
| Penicillin V                               | 1.5   |
| Pentachlorophenol (PCP)                    | 10  |
| Pentamethyl-4,6-dinitroindane              | 0.35  |
| Pentetic acid                              | 250   |
| Permethrin                                 | 100   |
| Phenanthrene                               | 150   |
| Phenol                                     | 150   |
| Phthalic anhydride                         | 7,000   |
| Picloram                                   | 300   |
| Piperonyl butoxide                         | 100   |
| Pirimicarb                                 | 5   |

| <b>Column 1</b>                            | <b>Column 2</b>   |
|--|---|
| <b>Factor</b>                              | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| Pirimiphos-ethyl                           | 0.5   |
| Pirimiphos-methyl                          | 50  |
| Praziquantel                               | 70  |
| Profenofos                                 | 0.3   |
| Progesterone                               | 105   |
| Promecarb                                  | 30  |
| Prometryn                                  | 105   |
| Propachlor                                 | 50  |
| Propanil                                   | 500   |
| Propargite                                 | 50  |
| Propazine                                  | 50  |
| Propiconazole                              | 100   |
| Propoxur                                   | 70  |
| Propranolol                                | 40  |
| Propylenedinitrilo tetraacetic acid (PDTA) | 0.7   |
| Propyzamide                                | 300   |
| Pyrazophos                                 | 30  |
| Pyrene                                     | 150   |
| Quintozene                                 | 30  |
| radiological compounds                     | 0.5 mSv/year<br>for the total<br>radionuclide<br>exposure                           |
| Ranitidine                                 | 26  |

## Schedule 3B

| <b>Column 1</b>                 | <b>Column 2</b>   |
|---------------------------------|---|
| <b>Factor</b>                   | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| Roxithromycin                   | 150   |
| Salbutamol                      | 3   |
| Salicylic acid                  | 105   |
| Selenium                        | 10  |
| Silver                          | 100   |
| Silvex (Fenoprop)               | 10  |
| Simazine                        | 20  |
| Stigmastanol                    | 1,000   |
| Styrene (vinyl benene)          | 30  |
| Sulfadiazine                    | 35  |
| Sulfamethazine (SMTZ)           | 35  |
| Sulfamethizole                  | 35  |
| Sulfamethoxazole                | 35  |
| Sulfamethoxine Sulfadimethoxine | 35  |
| Sulfasalazine                   | 500   |
| Sulfate                         | 500,000   |
| Sulfathiazole                   | 35  |
| Sulprofos                       | 10  |
| 2,4,5-Trichlorophenol           | 350   |
| 2,4,6-Trichlorophenol (2,4,6-T) | 20  |
| 4-Tert Octylphenol              | 50  |
| Temazepam                       | 5   |
| Temephos                        | 300   |



| <b>Column 1</b>                 | <b>Column 2</b>   |
|---------------------------------|---|
| <b>Factor</b>                   | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| Terbacil                        | 30  |
| Terbufos                        | 0.5   |
| Terbutaline                     | 4.5   |
| Terbutryn                       | 300   |
| Terramycin (oxytetracycline)    | 105   |
| Testosterone                    | 7   |
| Tetrachloroethene               | 50  |
| Tetrachlorvinphos               | 100   |
| Tetracycline (TCLN)             | 105   |
| Theophylline                    | 1.5   |
| Thiobencarb                     | 30  |
| Thiometon                       | 3   |
| Thiophanate                     | 5   |
| Thiram                          | 3   |
| Timolol                         | 10  |
| Tolfenamic acid                 | 17.5  |
| Toluene                         | 800   |
| Triadimefon                     | 2   |
| Tri(butyl cellosolve) phosphate | 50  |
| Tributyl phosphate              | 0.5   |
| Tributyltin oxide               | 1   |
| Tributyltin (TBT)               | 1   |
| Trichlorfon                     | 5   |

Schedule 3B

---

| <b>Column 1</b>                         | <b>Column 2</b>   |
|---|---|
| <b>Factor</b>                           | <b>Value</b><br><b>(µg/L</b><br><b>unless</b><br><b>otherwise</b><br><b>stated)</b> |
| Trichloroacetaldehyde (chloral hydrate) | 20  |
| Trichloroacetic acid                    | 100   |
| Trichlorophenoxyacetic acid (2,4,5-T)   | 100   |
| Triclopyr                               | 10  |
| Triclosan                               | 0.35  |
| Trifluralin                             | 50  |
| Trimethoprim                            | 70  |
| Triphenyl phosphate                     | 1   |
| Tris(2-chloroethyl)phosphate (TCEP)     | 1   |
| Tylosin                                 | 1,050   |
| Uranium                                 | 20  |
| Vanadium                                | 50  |
| Venlafaxine                             | 75  |
| Vernolate                               | 30  |
| Vinyl chloride                          | 0.3   |
| Warfarin                                | 1.5   |
| Xylene                                  | 600   |
| Zinc                                    | 3,000   |

## Schedule 3C Standards for quality of class A+ recycled water

### section 18AE

| Column 1<br>Factor   | Column 2<br>Frequency of sampling | Column 3<br>Value   | Column 4<br>Annual value  |
|--|-----------------------------------|---|---|
| chlorine residual, if the water is supplied through a dual reticulation scheme | daily                             | (a) for a sample mentioned in section 18AE(c)—less than 0.2mg/L; or<br>(b) for a follow-up sample mentioned in section 18AE(d)—more than 0.5mg/L          | more than 0.5mg/L found in 95% of the samples taken for a 12 month period     |
| <i>Clostridium perfringens</i>   | weekly                            | (a) for a sample mentioned in section 18AE(c)—more than 10 cfu/100mL; or<br>(b) for a follow-up sample mentioned in section 18AE(d)—less than 1 cfu/100mL | less than 1 cfu/100mL found in 95% of the samples taken for a 12 month period |
| <i>Escherichia coli</i>  | weekly                            | (a) for a sample mentioned in section 18AE(c)—more than 10 cfu/100mL; or<br>(b) for a follow-up sample mentioned in section 18AE(d)—less than 1 cfu/100mL | less than 1 cfu/100mL found in 95% of the samples taken for a 12 month period |

## Schedule 3C

| <b>Column 1</b>      | <b>Column 2</b>              | <b>Column 3</b>   | <b>Column 4</b>   |
|----------------------|------------------------------|---|---|
| <b>Factor</b>        | <b>Frequency of sampling</b> | <b>Value</b>  | <b>Annual value</b>   |
| F-RNA bacteriophages | weekly                       | (a) for a sample mentioned in section 18AE(c)—more than 10 pfu/100mL; or<br>(b) for a follow-up sample mentioned in section 18AE(d)—less than 1 pfu/100mL | less than 1 pfu/100mL found in 95% of the samples taken for a 12 month period |
| somatic coliphages   | weekly                       | (a) for a sample mentioned in section 18AE(c)—more than 10 pfu/100mL; or<br>(b) for a follow-up sample mentioned in section 18AE(d)—less than 1 pfu/100mL | less than 1 pfu/100mL found in 95% of the samples taken for a 12 month period |
| turbidity            | daily                        | (a) for a sample mentioned in section 18AE(c)—more than 5 NTU; or<br>(b) for a follow-up sample mentioned in section 18AE(d)—less than 2 NTU              | less than 2 NTU found in 95% of the samples taken for a 12 month period       |

## Schedule 3D Standards for quality of classes A, B, C and D recycled water

section 18AF

| Column 1                | Column 2                | Column 3              | Column 4   | Column 5  |
|-------------------------|-------------------------|-----------------------|--|---|
| Class of recycled water | Factor                  | Frequency of sampling | Value  | Annual value  |
| class A recycled water  | <i>Escherichia coli</i> | weekly                | (a) for a sample mentioned in section 18AF(c) —more than 100 cfu/100mL; or<br>(b) for a follow-up sample mentioned in section 18AF(d) — less than 10 cfu/100mL   | less than 10 cfu/100mL found in 95% of the samples taken for a 12 month period  |
| class B recycled water  | <i>Escherichia coli</i> | weekly                | (a) for a sample mentioned in section 18AF(c) —more than 1,000 cfu/100mL; or<br>(b) for a follow-up sample mentioned in section 18AF(d) —less than 100 cfu/100mL | less than 100 cfu/100mL found in 95% of the samples taken for a 12 month period |

## Schedule 3D

| <b>Column 1</b>                | <b>Column 2</b>         | <b>Column 3</b>              | <b>Column 4</b>   | <b>Column 5</b>  |
|--------------------------------|-------------------------|------------------------------|---|--|
| <b>Class of recycled water</b> | <b>Factor</b>           | <b>Frequency of sampling</b> | <b>Value</b>  | <b>Annual value</b>  |
| class C recycled water         | <i>Escherichia coli</i> | weekly                       | (a) for a sample mentioned in section 18AF(c) —more than 10,000 cfu/100mL; or<br><br>(b) for a follow-up sample mentioned in section 18AF(d) —less than 1,000 cfu/100mL   | less than 1,000 cfu/100mL found in 95% of the samples taken for a 12 month period  |
| class D recycled water         | <i>Escherichia coli</i> | weekly                       | (a) for a sample mentioned in section 18AF(c) —more than 100,000 cfu/100mL; or<br><br>(b) for a follow-up sample mentioned in section 18AF(d) —less than 10,000 cfu/100mL | less than 10,000 cfu/100mL found in 95% of the samples taken for a 12 month period |

## Schedule 3E Standards for quality of recycled water for irrigating minimally processed food crops

section 18AG

| <b>Column 1</b><br><b>Type of crop</b>   | <b>Column 2</b><br><b>Method of irrigation</b> | <b>Column 3</b><br><b>Class of recycled water</b> |
|--|--|---|
| root crops<br><i>Examples of crops—</i><br>carrot and onion  | spray, drip, flood, furrow<br>or subsurface    | class A recycled<br>water                         |
| crops with produce, other than<br>rockmelons, grown on or near the<br>ground if the produce is normally<br>eaten with the skin removed<br><br><i>Example of crop—</i><br>pumpkin | spray  | class B recycled<br>water                         |
| rockmelons   | subsurface, drip, flood or<br>furrow           | class C recycled<br>water                         |
| rockmelons   | spray, drip, flood, furrow<br>or subsurface    | class A+ recycled<br>water                        |

## Schedule 3E

| <b>Column 1</b>  | <b>Column 2</b>                   | <b>Column 3</b>                |
|--|-----------------------------------|--------------------------------|
| <b>Type of crop</b>  | <b>Method of irrigation</b>       | <b>Class of recycled water</b> |
| crops with produce grown on or near the ground, other than crops with produce normally eaten with the skin removed | spray, flood and furrow           | class A+ recycled water        |
| <i>Examples of crops—</i>  |                                   |                                |
| broccoli, cabbage and tomato   |                                   |                                |
|  | drip                              | class A recycled water         |
|  | subsurface                        | class C recycled water         |
| crops with produce grown away from the ground if the produce is normally eaten with the skin removed               | spray                             | class B recycled water         |
| <i>Examples of crops—</i>  |                                   |                                |
| avocado, banana and mango  |                                   |                                |
|  | drip, flood, furrow or subsurface | class C recycled water         |
| crops with produce grown away from the ground, other than crops with produce normally eaten with the skin removed  | spray                             | class A+ recycled water        |
| <i>Examples of crops—</i>  |                                   |                                |
| apple, olive and peach   |                                   |                                |
|  | drip, flood or furrow             | class B recycled water         |
|  | subsurface                        | class C recycled water         |



---

| <b>Column 1</b>   | <b>Column 2</b>             | <b>Column 3</b>                |
|---|-----------------------------|--------------------------------|
| <b>Type of crop</b>   | <b>Method of irrigation</b> | <b>Class of recycled water</b> |
| crops for produce grown in hydroponic conditions<br><i>Examples of crops—</i><br>herb and lettuce | hydroponic                  | class A+ recycled water        |

## Schedule 4 Dictionary

### section 2AA

*ACM*, for part 1A, division 1, see section 2B.

*asbestos*, for part 1A, division 1, see section 2B.

*associated asbestos waste*, for part 1A, division 1, see section 2B.

*bonded ACM*, for part 1A, division 1, see section 2B.

*cfu* means colony forming units.

*chlorine residual* see section 18AB.

*class A+ recycled water* see section 18AB.

*class A recycled water* see section 18AB.

*class B recycled water* see section 18AB.

*class C recycled water* see section 18AB.

*class D recycled water* see section 18AB.

*confirms*, for schedule 2A, see schedule 2A, part 3, section 1.

*diagnosed*, for schedule 2A, see schedule 2A, part 3, section 1.

*drinking water service* see section 18AB.

*dual reticulation scheme* see section 18AB.

*fluoridated water* see the *Water Fluoridation Regulation 2008*, schedule 3.

*free chlorine* see section 18AB.

*friable ACM*, for part 1A, division 1, see section 2B.

*Menzies School of Health Research* means the school established under the *Menzies School of Health Research Act* (NT), section 4.

*minimally processed food crop* see section 18AB.

---

**mosquito**, for part 1A, division 2, see section 2L.

**mSv** means a millisievert.

**non-workplace area**, for part 1A, division 1, see section 2B.

**NTU** means nephelometric turbidity units.

**occupational exposure policy** means a document stating the minimum procedures for the immediate assessment, management and follow up of a person exposed to blood borne viruses or other infectious agents from blood or another bodily fluid from a work related activity.

**pfu** means plaque forming units.

**prescribed work**, for part 1A, division 1, see section 2B.

**recycled water** see section 18AB.

**relevant contact**, for schedule 2A, see schedule 2A, part 3, section 1.

**relevant person**, for a place, for part 1A, division 2, see section 2L.

**relevant structure**, for part 1A, division 3, see section 2S.

**relevant tank**, for part 1A, division 2, see section 2L.

**remove**, for part 1A, division 1, see section 2B.

**reused** see section 18AB.

**service provider** see section 18AB.

**sharps** means objects or devices capable of inflicting a penetrating injury.

**sharps disposal policy** means a document stating the minimum procedures for disposing of sharps to minimise—

- (a) the risk of injury to a person; and
- (b) the transmission of blood borne viruses and other infectious agents to a person.

**suspected**, for schedule 2A, see schedule 2A, part 3, section 1.

**symptoms**, for schedule 2A, see schedule 2A, part 3, section 1.

***University of Melbourne*** means the university established under the *Melbourne University Act 1958* (Vic), section 4.

## 1 Index to endnotes

- 2 Key
- 3 Table of reprints
- 4 List of legislation
- 5 List of annotations

## 2 Key

### Key to abbreviations in list of legislation and annotations

| Key         | Explanation                           | Key           | Explanation                |
|-------------|---------------------------------------|---------------|----------------------------|
| <b>AIA</b>  | = <b>Acts Interpretation Act 1954</b> | <b>(prev)</b> | = <b>previously</b>        |
| <b>amd</b>  | = <b>amended</b>                      | <b>proc</b>   | = <b>proclamation</b>      |
| <b>amd</b>  | = <b>amendment</b>                    | <b>prov</b>   | = <b>provision</b>         |
| <b>t</b>    |                                       |               |                            |
| <b>ch</b>   | = <b>chapter</b>                      | <b>pt</b>     | = <b>part</b>              |
| <b>def</b>  | = <b>definition</b>                   | <b>pubd</b>   | = <b>published</b>         |
| <b>div</b>  | = <b>division</b>                     | <b>R[X]</b>   | = <b>Reprint No. [X]</b>   |
| <b>exp</b>  | = <b>expires/expired</b>              | <b>RA</b>     | = <b>Reprints Act 1992</b> |
| <b>gaz</b>  | = <b>gazette</b>                      | <b>reloc</b>  | = <b>relocated</b>         |
| <b>hdg</b>  | = <b>heading</b>                      | <b>renu</b>   | = <b>renumbered</b>        |
|             |                                       | <b>m</b>      |                            |
| <b>ins</b>  | = <b>inserted</b>                     | <b>rep</b>    | = <b>repealed</b>          |
| <b>lap</b>  | = <b>lapsed</b>                       | <b>(retro</b> | = <b>retrospectively</b>   |
|             |                                       | <b>)</b>      |                            |
| <b>notf</b> | = <b>notified</b>                     | <b>rv</b>     | = <b>revised version</b>   |
| <b>d</b>    |                                       |               |                            |
| <b>num</b>  | = <b>numbered</b>                     | <b>s</b>      | = <b>section</b>           |

| <b>Key</b>    | <b>Explanation</b>        | <b>Key</b>     | <b>Explanation</b>                             |
|---------------|---------------------------|----------------|--|
| <b>o in c</b> | = <b>order in council</b> | <b>sch</b>     | = <b>schedule</b>                              |
| <b>om</b>     | = <b>omitted</b>          | <b>sdiv</b>    | = <b>subdivision</b>                           |
| <b>orig</b>   | = <b>original</b>         | <b>SIA</b>     | = <b>Statutory Instruments Act 1992</b>        |
| <b>p</b>      | = <b>page</b>             | <b>SIR</b>     | = <b>Statutory Instruments Regulation 2012</b> |
| <b>para</b>   | = <b>paragraph</b>        | <b>SL</b>      | = <b>subordinate legislation</b>               |
| <b>prec</b>   | = <b>preceding</b>        | <b>sub</b>     | = <b>substituted</b>                           |
| <b>pres</b>   | = <b>present</b>          | <b>unnum m</b> | = <b>unnumbered</b>                            |
| <b>prev</b>   | = <b>previous</b>         |                |  |

### 3 Table of reprints

A new reprint of the legislation is prepared by the Office of the Queensland Parliamentary Counsel each time a change to the legislation takes effect.

The notes column for this reprint gives details of any discretionary editorial powers under the **Reprints Act 1992** used by the Office of the Queensland Parliamentary Counsel in preparing it. Section 5(c) and (d) of the Act are not mentioned as they contain mandatory requirements that all amendments be included and all necessary consequential amendments be incorporated, whether of punctuation, numbering or another kind. Further details of the use of any discretionary editorial power noted in the table can be obtained by contacting the Office of the Queensland Parliamentary Counsel by telephone on 3003 9601 or email [legislation.queries@oqpc.qld.gov.au](mailto:legislation.queries@oqpc.qld.gov.au).

From 29 January 2013, all Queensland reprints are dated and authorised by the Parliamentary Counsel. The previous numbering system and distinctions between printed and electronic reprints is not continued with the relevant details for historical reprints included in this table.

| <b>Reprint No.</b> | <b>Amendments included</b> | <b>Effective</b> | <b>Notes</b> |
|--------------------|----------------------------|------------------|--------------|
| 0A                 | none                       | 1 December 2005  |              |
| 1                  | none                       | 16 January 2006  |              |

| <b>Reprint No.</b>   | <b>Amendments included</b>                            | <b>Effective</b>           | <b>Notes</b>          |
|----------------------|---|----------------------------|-----------------------|
| 1A                   | 2006 SL No. 91  | 19 May 2006                |                       |
| 1B                   | 2006 SL No. 308                                       | 15 December 2006           |                       |
| 1C                   | 2007 SL No. 86  | 18 June 2007               |                       |
| 1D                   | 2008 SL No. 9   | 1 February 2008            |                       |
| 1E                   | 2008 SL No. 218                                       | 4 July 2008                |                       |
| 1F                   | 2008 SL No. 392                                       | 5 December 2008            |                       |
| 1G                   | 2008 SL No. 420                                       | 12 December 2008           |                       |
| 1H                   | 2009 SL No. 72  | 28 May 2009                | R1H withdrawn, see R2 |
| 2                    | —   | 28 May 2009                |                       |
| 2A                   | 2009 SL No. 234                                       | 30 October 2009            |                       |
| 2B                   | 2010 SL No. 370                                       | 10 December 2010           |                       |
| 2C                   | 2011 Act No. 18                                       | 6 June 2011                |                       |
| 2D                   | 2011 SL No. 128                                       | 1 July 2011                |                       |
| 2E                   | 2011 Act No. 18<br>2011 SL No. 240<br>2011 SL No. 278 | 1 January 2012             |                       |
| 2F                   | 2012 SL No. 208                                       | 23 November 2012           |                       |
| 2G                   | 2012 SL No. 208                                       | 25 November 2012           |                       |
| <b>Current as at</b> |   | <b>Amendments included</b> | <b>Notes</b>          |
| 1 January 2014       |   | 2013 SL No. 265            |                       |
| 1 March 2014         |   | 2014 SL No. 19             | RA s 35               |
| 1 September 2015     |   | 2015 SL No. 96             | RA s 44               |

| <b>Current as at</b> | <b>Amendments included</b>         | <b>Notes</b> |
|----------------------|------------------------------------|--------------|
| 1 January 2016       | 2015 SL No. 154<br>2015 SL No. 175 | RA s 26(1)   |
| 16 December 2016     | 2016 SL No. 237                    |              |
| 1 February 2017      | 2016 SL No. 225                    |              |
| 2 June 2017          | 2017 SL No. 79                     | RA s 35      |
| 30 June 2017         | 2017 SL No. 107                    |              |

## **4 List of legislation**

### **Regulatory impact statements**

For subordinate legislation that has a regulatory impact statement, specific reference to the statement is included in this list.

### **Explanatory notes**

All subordinate legislation made on or after 1 January 2011 has an explanatory note. For subordinate legislation made before 1 January 2011 that has an explanatory note, specific reference to the note is included in this list.

### **Public Health Regulation 2005 SL No. 281**

made by the Governor in Council on 24 November 2005

notfd gaz 25 November 2005 pp 1132–3

ss 1–2 commenced on date of notification

pt 7 commenced 16 January 2006 (see s 2(2))

remaining provisions commenced 1 December 2005 (see s 2(1))

exp 31 August 2017 (see SIA s 56A(2) and SIR s 3 sch 2 pt 2)

Note—The expiry date may have changed since this reprint was published. See the latest reprint of the SIR for any change.  
amending legislation—

### **Health Legislation Amendment Regulation (No. 3) 2006 SL No. 91 s 1, pt 3**

notfd gaz 19 May 2006 pp 252–4

commenced on date of notification

### **Health Legislation Amendment Regulation (No. 7) 2006 SL No. 308 pts 1, 5**

notfd gaz 15 December 2006 pp 1861–5

commenced on date of notification

### **Public Health and Other Legislation Amendment Regulation (No. 1) 2007 SL No. 86 pts 1, 3**

notfd gaz 18 May 2007 pp 345–8



ss 1–2 commenced on date of notification  
remaining provisions commenced 18 June 2007 (see s 2)  
Note—A regulatory impact statement and explanatory note were prepared.

**Health Legislation Amendment Regulation (No. 1) 2008 SL No. 9 pts 1, 5**

notfd gaz 1 February 2008 pp 465–7  
commenced on date of notification

**Public Health Amendment Regulation (No. 1) 2008 SL No. 218**

notfd gaz 4 July 2008 pp 1420–1  
commenced on date of notification

**Public Health Amendment Regulation (No. 2) 2008 SL No. 392**

notfd gaz 5 December 2008 pp 1840–3  
commenced on date of notification

**Health Legislation Amendment Regulation (No. 5) 2008 SL No. 420 s 1, pt 16**

notfd gaz 12 December 2008 pp 2044–53  
commenced on date of notification

**Public Health Amendment Regulation (No. 1) 2009 SL No. 72**

notfd gaz 28 May 2009 pp 335–6  
commenced on date of notification

**Public Health Amendment Regulation (No. 2) 2009 SL No. 234**

notfd gaz 30 October 2009 pp 657–8  
commenced on date of notification

**Health Legislation Amendment Regulation (No. 4) 2010 SL No. 370 s 1, pt 4**

notfd gaz 10 December 2010 pp 1082–6  
commenced on date of notification

**Work Health and Safety Act 2011 No. 18 ss 1–2, pt 17 div 2, s 404 sch 4 pt 2 div 1**

date of assent 6 June 2011  
ss 1–2, pt 17 div 2 commenced on date of assent (see s 2)  
remaining provisions commenced 1 January 2012 (2011 SL No. 238)

**Health Legislation Amendment Regulation (No. 3) 2011 SL No. 128 s 1, pt 4**

notfd gaz 1 July 2011 pp 589–96  
commenced on date of notification

**Work Health and Safety Regulation 2011 SL No. 240 ss 1, 2(4), ch 14 pt 14.8**

notfd gaz 25 November 2011 pp 603–6  
ss 1–2 commenced on date of notification  
remaining provisions commenced 1 January 2012 on the commencement of s 277 of  
the Act (see s 2(4) and 2011 SL No. 238)

**Education and Care Services National Law (Queensland) Regulation 2011 SL No. 278 pts 1, 7**

notfd gaz 9 December 2011 pp 729–35  
ss 1–2 commenced on date of notification  
remaining provisions commenced 1 January 2012 (see s 2)

**Health Legislation Amendment Regulation (No. 2) 2012 SL No. 208 pts 1, 4**

notfd gaz 23 November 2012 pp 391–2  
ss 1–2 commenced on date of notification  
ss 19–21, 23 commenced on date of notification  
remaining provisions commenced 25 November 2012 (see s 2)

**Education and Care Services Regulation 2013 SL No. 265 ss 1–2, 81 sch 5 pt 2**

notfd <www.legislation.qld.gov.au> 6 December 2013  
ss 1–2 commenced on date of notification  
remaining provisions commenced 1 January 2014 (see s 2)

**Public Health Amendment Regulation (No. 1) 2014 SL No. 19**

notfd <www.legislation.qld.gov.au> 28 February 2014  
ss 1–2 commenced on date of notification  
remaining provisions commenced 1 March 2014 (see s 2)

**Health Legislation Amendment Regulation (No. 2) 2015 SL No. 96 pts 1–2**

notfd <www.legislation.qld.gov.au> 21 August 2015  
ss 1–2 commenced on date of notification  
remaining provisions commenced 1 September 2015 (see s 2)

**Health Legislation Amendment Regulation (No. 3) 2015 SL No. 154 ss 1–2(1), pt 6**

notfd <www.legislation.qld.gov.au> 6 November 2015  
ss 1–2 commenced on date of notification  
remaining provisions commenced 1 January 2016 (see s 2(1))

**Public Health Amendment Regulation (No. 1) 2015 SL No. 175**

notfd <www.legislation.qld.gov.au> 11 December 2015  
ss 1–2 commenced on date of notification  
s 7(5)–(6), (8) commenced 1 January 2016 (see s 2) (amdt could not be given effect)  
remaining provisions commenced 1 January 2016 (see s 2)

**Public Health (Water Risk Management) Amendment Regulation 2016 SL No. 225**

notfd <www.legislation.qld.gov.au> 9 December 2016  
ss 1–2 commenced on date of notification  
ss 3–4 commenced 1 February 2017 (see s 2)

**Health Legislation Amendment Regulation (No. 2) 2016 SL No. 237 pts 1, 3**

notfd <www.legislation.qld.gov.au> 16 December 2016  
commenced on date of notification

**Public Health (Infection Control) Amendment Regulation 2017 SL No. 79**

notfd <www.legislation.qld.gov.au> 2 June 2017  
commenced on date of notification

**Health Legislation Amendment Regulation (No. 1) 2017 SL No. 107**

notfd <www.legislation.qld.gov.au> 30 June 2017  
s 1, pt 4 commenced on date of notification

## 5 List of annotations

### Dictionary

s 2AA ins 2007 SL No. 86 s 8

## **PART 1A—PUBLIC HEALTH RISKS**

**pt hdg** ins 2007 SL No. 86 s 9

### **Division 1—Asbestos**

**div hdg** ins 2007 SL No. 86 s 9

#### **Purpose and application of div 1**

s 2A ins 2007 SL No. 86 s 9  
amd 2011 SL No. 128 s 15

#### **Definitions for div 1**

s 2B ins 2007 SL No. 86 s 9  
def *asbestos* sub 2011 Act No. 18 s 311  
def *non-workplace area* amd 2011 Act No. 18 s 404 sch 4 pt 2 div 1  
sub 2011 SL No. 240 s 813  
amd 2016 SL No. 237 s 5

#### **Administration and enforcement of div 1**

s 2C ins 2007 SL No. 86 s 9

#### **Removal of friable asbestos**

s 2D ins 2007 SL No. 86 s 9  
amd 2011 Act No. 18 s 404 sch 4 pt 2 div 1  
sub 2011 SL No. 240 s 814

#### **Removal of bonded ACM**

s 2E ins 2007 SL No. 86 s 9  
amd 2011 Act No. 18 s 404 sch 4 pt 2 div 1  
sub 2011 SL No. 240 s 814

#### **Cleaning or cutting ACM**

s 2F ins 2007 SL No. 86 s 9

#### **Requirement to seal bonded ACM if broken**

s 2G ins 2007 SL No. 86 s 9

#### **Requirement to take reasonable measures to minimise release of asbestos fibres**

s 2H ins 2007 SL No. 86 s 9

#### **Packaging and disposal of associated asbestos waste**

s 2I ins 2007 SL No. 86 s 9

#### **Prohibition on selling or giving away ACM**

s 2J ins 2007 SL No. 86 s 9

### **Division 2—Mosquitos**

**div hdg** ins 2007 SL No. 86 s 9

#### **Purpose of div 2**

s 2K ins 2007 SL No. 86 s 9  
amd 2012 SL No. 208 s 19

#### **Definitions for div 2**

s **2L** ins 2007 SL No. 86 s 9

**Administration and enforcement of div 2**

s **2M** ins 2007 SL No. 86 s 9

**Requirement to ensure place is not a breeding ground for mosquitos**

s **2N** ins 2007 SL No. 86 s 9

**Construction, installation and maintenance of a relevant tank**

s **2O** ins 2007 SL No. 86 s 9

**Requirements for a relevant tank**

s **2P** ins 2007 SL No. 86 s 9

**Offence to damage screen or flap valve**

s **2Q** ins 2007 SL No. 86 s 9

**Division 3—Rats and mice**

div **hdg** ins 2007 SL No. 86 s 9

**Purpose of div 3**

s **2R** ins 2007 SL No. 86 s 9  
amd 2012 SL No. 208 s 20

**Definition for div 3**

s **2S** ins 2007 SL No. 86 s 9

**Administration and enforcement of div 3**

s **2T** ins 2007 SL No. 86 s 9

**Requirement for owner of relevant structure**

s **2U** ins 2007 SL No. 86 s 9

**Offence to damage screen etc. on relevant structure**

s **2V** ins 2007 SL No. 86 s 9

**Requirement to ensure rats or mice do not live or breed on land around dwelling**

s **2W** ins 2007 SL No. 86 s 9

**Requirements about keeping rats or mice as pets etc.**

s **2X** ins 2007 SL No. 86 s 9

**Division 4—Other public health risks**

div **hdg** ins 2017 SL No. 79 s 3

**Invasive procedures—Act, ss 11 and 18**

s **2XA** ins 2017 SL No. 79 s 3

**PART 1B—WATER RISK MANAGEMENT PLANS**

pt **hdg** ins 2016 SL No. 225 s 4

**Prescribed tests—Act, s 61A**

s **2Y** ins 2016 SL No. 225 s 4

**Prescribed requirement—Act, s 61D**

s **2Z** ins 2016 SL No. 225 s 4

**Prescribed reporting period—Act, s 61I**  
s 2ZA ins 2016 SL No. 225 s 4

**Prescribed agreements—Act, s 84(1)**  
s 12AA ins 2008 SL No. 392 s 3  
sub 2017 SL No. 107 s 14

**PART 2A—INFECTION CONTROL**  
pt hdg ins 2006 SL No. 308 s 29

**Prescribed facilities—Act, s 149(3)(b)**  
s 12A ins 2006 SL No. 308 s 29  
om 2008 SL No. 392 s 4

**Prescribed health care facilities—Act, s 153(3)**  
s 12AB ins 2008 SL No. 392 s 4

**Prescribed health care facilities—Act, s 154(3)**  
s 12AC ins 2008 SL No. 392 s 4

**PART 2B—CHILD HEALTH—CONTAGIOUS CONDITIONS**  
pt hdg ins 2007 SL No. 86 s 10

**Contagious condition—Act, s 158, definition contagious condition**  
s 12B ins 2007 SL No. 86 s 10  
amd 2015 SL No. 175 s 4

**Requirements for vaccination—Act, s 158, definition vaccinated**  
s 12C ins 2007 SL No. 86 s 10  
amd 2012 SL No. 208 s 21

**Vaccine preventable condition—Act, s 158, definition vaccine preventable condition**  
s 12D ins 2007 SL No. 86 s 10  
amd 2015 SL No. 175 s 5

**Prescribed period for a contagious condition—Act, s 160**  
s 12E ins 2007 SL No. 86 s 10  
amd 2012 SL No. 208 s 22; 2013 SL No. 265 s 81 sch 5 pt 2; 2015 SL No. 175 s 6

**PART 2C—PERFORMANCE OF COSMETIC PROCEDURES ON CHILDREN**  
pt 2C (s 12F) ins 2009 SL No. 234 s 3

**PART 2D—DISCLOSURE OF INFORMATION FOR SCHOOL HEALTH PROGRAMS**  
pt hdg ins 2016 SL No. 237 s 6

**Prescribed information for school health programs—Act, s 213AD**  
s 12G ins 2016 SL No. 237 s 6

**Prescribed agreements—Act, s 226(1)(a)(i)(B)**  
s 14 amd 2008 SL No. 392 s 5  
reloc 2017 SL No. 107 s 15

**PART 3A—MATERNAL DEATH STATISTICS**  
pt hdg ins 2014 SL No. 19 s 4

om 2017 SL No. 107 s 16

**Notifications about maternal death statistics—Act, s 228F**

s 13A ins 2014 SL No. 19s 4

amd 2016 SL No. 237 s 7

om 2017 SL No. 107 s 16

**PART 4—MATERNAL DEATH STATISTICS**

**pt hdg** sub 2017 SL No. 107 s 16

**Notifications about maternal death statistics—Act, s 228F**

s 14A ins 2017 SL No. 107 s 16

**Prescribed agreements—Act, s 228O(1)(a)(i)(B)**

s 14B ins 2017 SL No. 107 s 16

**Prescribed person—Act, s 232**

s 15A ins 2016 SL No. 237 s 8

**Prescribed agreements—Act, s 244(1)(a)(i)(B)**

s 17 amd 2008 SL No. 392 s 6; 2017 SL No. 107 s 17

**PART 6A—WATER QUALITY**

**pt hdg** ins 2008 SL No. 218 s 3

**Division 1—Preliminary**

**div 1** (ss 18AA–18AB) ins 2008 SL No. 218 s 3

**Division 2—Standards for water quality—Act, s 461(2)**

**div hdg** ins 2008 SL No. 218 s 3

**Drinking water**

s 18AC ins 2008 SL No. 218 s 3

amd 2008 SL No. 420 s 53

**Recycled water supplied to augment a supply of drinking water**

s 18AD ins 2008 SL No. 218 s 3

**Class A+ recycled water**

s 18AE ins 2008 SL No. 218 s 3

**Class A, B, C or D recycled water**

s 18AF ins 2008 SL No. 218 s 3

**Recycled water for irrigation of minimally processed food crops**

s 18AG ins 2008 SL No. 218 s 3

**Recycled water supplied for a dual reticulation scheme**

s 18AH ins 2008 SL No. 218 s 3

**Paint—Act, s 60**

s 18A ins 2008 SL No. 9 s 9

**Emergency officers (general)—Act, s 333(1)(e)**

s 19 ins 2006 SL No. 91 s 17

**Human research ethics committee—Act, sch 2, definition human research ethics committee**

s 20 (prev s 19) renum 2006 SL No. 91 s 16  
amd 2012 SL No. 208 s 23

**Prescribed training for indemnity conditions—Act, s 454G**

s 20A ins 2015 SL No. 96 s 4

**PART 8—TRANSITIONAL PROVISIONS**

pt hdg ins 2011 SL No. 240 s 815

**Transitional asbestos removal licence or certificate**

s 21 ins 2011 SL No. 240 s 815

**SCHEDULE 1—NOTIFIABLE CONDITIONS**

amd 2006 SL No. 91 s 18  
sub 2008 SL No. 392 s 7  
amd 2015 SL No. 154 s 19; 2017 SL No. 107 s 18

**SCHEDULE 2—IMMEDIATE NOTIFICATIONS**

amd 2008 SL No. 392 s 8; 2015 SL No. 154 s 20

**SCHEDULE 2A—CONTAGIOUS CONDITIONS**

ins 2007 SL No. 86 s 11  
amd 2008 SL No. 392 s 9; 2009 SL No. 72 s 3; 2011 SL No. 278 s 16; 2012 SL No. 208 s 24; 2013 SL No. 265 s 81 sch 5 pt 2; 2015 SL No. 154 s 21; 2015 SL No. 175 s 7(1)–(4), (7), (9)–(11) ((5)–(6), (8) amdt could not be given effect)

**SCHEDULE 2B—VACCINE PREVENTABLE CONDITIONS**

ins 2015 SL No. 175 s 8

**SCHEDULE 3—AGREEMENTS**

amd 2008 SL No. 392 s 10; 2010 SL No. 370 s 9; 2017 SL No. 107 s 19

**SCHEDULE 3A—STANDARDS FOR QUALITY OF DRINKING WATER**

ins 2008 SL No. 218 s 4  
amd 2008 SL No. 420 s 54

**SCHEDULE 3B—STANDARDS FOR QUALITY OF RECYCLED WATER SUPPLIED TO AUGMENT A SUPPLY OF DRINKING WATER**

ins 2008 SL No. 218 s 4

**SCHEDULE 3C—STANDARDS FOR QUALITY OF CLASS A+ RECYCLED WATER**

ins 2008 SL No. 218 s 4

**SCHEDULE 3D—STANDARDS FOR QUALITY OF CLASSES A, B, C AND D RECYCLED WATER**

ins 2008 SL No. 218 s 4

**SCHEDULE 3E—STANDARDS FOR QUALITY OF RECYCLED WATER FOR IRRIGATING MINIMALLY PROCESSED FOOD CROPS**

ins 2008 SL No. 218 s 4

**SCHEDULE 4—DICTIONARY**

ins 2007 SL No. 86 s 12  
def *cfu* ins 2008 SL No. 218 s 5  
def *chlorine residual* ins 2008 SL No. 218 s 5  
def *class A+ recycled water* ins 2008 SL No. 218 s 5  
def *class A recycled water* ins 2008 SL No. 218 s 5  
def *class B recycled water* ins 2008 SL No. 218 s 5  
def *class C recycled water* ins 2008 SL No. 218 s 5  
def *class D recycled water* ins 2008 SL No. 218 s 5  
def *confirms* ins 2012 SL No. 208 s 25  
def *diagnosed* ins 2012 SL No. 208 s 25  
def *drinking water service* ins 2008 SL No. 218 s 5  
def *dual reticulation scheme* ins 2008 SL No. 218 s 5  
def *fluoridated water* ins 2008 SL No. 420 s 55  
def *free chlorine* ins 2008 SL No. 218 s 5  
def *Menzies School of Health Research* ins 2017 SL No. 107 s 20  
def *minimally processed food crop* ins 2008 SL No. 218 s 5  
def *mSv* ins 2008 SL No. 218 s 5  
def *NTU* ins 2008 SL No. 218 s 5  
def *occupational exposure policy* ins 2008 SL No. 392 s 11  
def *pfu* ins 2008 SL No. 218 s 5  
def *recycled water* ins 2008 SL No. 218 s 5  
def *relevant contact* ins 2012 SL No. 208 s 25  
def *reused* ins 2008 SL No. 218 s 5  
def *service provider* ins 2008 SL No. 218 s 5  
def *sharps* ins 2008 SL No. 392 s 11  
def *sharps disposal policy* ins 2008 SL No. 392 s 11  
def *suspected* ins 2012 SL No. 208 s 25  
def *symptoms* ins 2012 SL No. 208 s 25  
def *University of Melbourne* ins 2008 SL No. 392 s 11

© State of Queensland 2017